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Abstract 
  Bacteria such as Escherichia coli, Campylobacter jejuni and Neisseria gonorrhoeae 
have developed various mechanisms to overcome toxic environments that are otherwise 
unfavorable for their survival.  One important strategy that bacteria use to expel toxic 
compounds, including heavy metal ions, is the expression of membrane efflux transporters that 
recognize and actively export these toxic compounds out of bacterial cells, thereby allowing 
them to survive in extremely toxic conditions.  Many of these transporters are multiple drug 
binding proteins which extrude different toxic chemicals and mediate a phenomenon of 
multidrug resistance (MDR) in bacteria.  The expression of these efflux transporters is tightly 
controlled at the transcriptional level by transcriptional regulators.  A number of these 
transcriptional regulators are also multidrug binding proteins, which recognize and respond to 
the same set of toxic chemicals that are expelled by the efflux transporters they regulate.  The 
goal of this Dissertation is to elucidate the structures and fundamental mechanisms that give 
rise to multiple drug recognition in these efflux transporters and their regulators.  We have 
determined several x-ray structures of these important proteins, including the E. coli AcrB 
efflux transporter, C. jejuni CmeR transcriptional regulator and E. coli CusB heavy-metal 
efflux protein.  We also crystallized the N. gonorrhoeae NorM multidrug transporter and 
collected the x-ray diffraction data of the crystals.  To gain further insight into the mechanism 
of multiple drug recognition, we examined the binding affinities of AcrB and AcrR to different 
drugs using fluorescence polarization assays.  In this thesis, we will summarize the new 
findings with AcrB, AcrR, CmeR and CusB, and discuss the structure and function of these 
efflux transporters and regulators.         
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CHAPTER 1. General Introduction 
 
Bacterial infections are commonly treated with various classes of antibiotics.  The 
clinical treatment is necessary for curing infectious diseases, but an unintended consequence of 
the treatment is the selection of bacterial pathogens with elevated levels of resistance to 
antibiotics.  Constant emergence and spread of antibiotic resistance has become a major threat 
to the health of humans and animals (1).  Bacterial organisms utilize multiple mechanisms to 
combat antibiotics and antimicrobial agents.  One important mechanism that gives rise to 
multidrug resistance (MDR) is the expression of multidrug efflux transporters that are capable 
of reducing the intracellular concentration of toxic compounds (2-6), thereby allowing the 
bacterial cells to survive in unfavorable environments.  Often a single organism can harbor 
multiple multidrug efflux transporters to secure its survival.  Currently, these multidrug efflux 
transporters can be divided into five different families: the resistance-nodulation-division 
(RND) family (7), the ATP-binding cassette (ABC) superfamily (8), the small multidrug 
resistance (SMR) family (9), the major facilitator (MF) superfamily (10-12), and the multidrug 
and toxic compound extrusion (MATE) family (13-14).  In Gram-negative bacteria, the most 
relevant multidrug efflux systems in terms of resistance to clinically important agents are 
members of the RND family (15), although members of the MFS, SMR, and MATE families 
also show a limited ability to promote resistance to some antibiotics (16). 
Typically, an RND transporter works in conjunction with a periplasmic membrane 
fusion protein (17) and an outer membrane channel (18).  The resulting tripartite efflux 
complex spans the inner and outer membranes of a bacterium and exports substrates directly 
out of the bacterial cell.  This process is driven by proton import, which is catalyzed by the 
inner membrane RND transporter.  As a Gram-negative bacterium, E. coli possesses seven 
transporters that belong to the RND family.  These transporters are responsible for the intrinsic 
tolerance of antibiotics and toxic compounds (7).  Among these seven transporters, six of them, 
AcrB (19-23), AcrD (24), AcrF (25), MdtB (26, 27), MdtC (26, 27) and YhiV (28), are 
multidrug efflux pumps.  They belong to the hydrophobic and amphiphilic efflux RND (HAE-
RND) protein family (7).  E. coli consists of only one heavy-metal efflux RND (HME-RND) 
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transporter, CusA, which specifically recognizes and confers resistance to Ag+ and Cu+ ions 
(29, 30). 
The novel MATE family of transporters was identified only quite recently.  The first 
well-characterized MATE transporter is Vibrio parahaemolyticus NorM, a multidrug Na+-
antiporter that confers resistance to dyes, fluoroquinolones and aminoalycosides (14).  
Recently, NorM of N. gonorrhoeae and N. meningitidis have been found and characterized (31, 
32).  Deletions of these pumps resulted in an increased susceptibility to cationic and neutral 
drugs (31).  Another MATE transporter, YdhE from E. coli has also been demonstrated to 
confer resistance to cationic and neutral antimicrobials (32, 33).  Currently, little is known 
about the structure and regulation of the MATE family.  Thus, there is a strong rationale for the 
investigation of this transporter family.        
The expression of multidrug efflux transporters is tightly controlled at the 
transcriptional level by regulators (2).  Many of these transcriptional factors are multidrug 
binding proteins, which recognize and respond to the same set of toxic chemicals that are 
exported by the transporters they regulate (34).  These transcriptional factors act as cytosolic 
chemical sensors and respond to threatening levels of toxic compounds (35, 36).  In bacteria, 
transcriptional regulation involves either one-component or two-component regulatory 
systems.  Two-component regulatory systems control protein expression through the function 
of a membrane-bound sensor kinase and a cytoplasmic response regulator, which is a DNA-
binding protein (36-38).  The membrane-bound kinase is responsible for receiving external 
signals and transmitting the information into the cell by phosphorylating the DNA-binding 
protein.  The phosphorylated DNA-binding protein then modulates gene transcription by 
interacting with its cognate DNA.  A key feature of two-component regulatory systems is the 
phosphorylation between sensor kinase and response regulator.  One-component bacterial 
transcriptional regulators modulate gene expression levels using a single two-domain protein 
where one domain receives signals and the other domain binds specific DNA sequences to 
regulate transcription (36).  Information flow between the two domains is through 
conformational changes, contrasting the phosphorylation events required in two-component 
systems.  Structural analyses revealed that almost 95% of all known prokaryotic transcriptional 
factors employ the helix-turn-helix (HTH) motif to bind their target DNAs (36).   Prokaryotic 
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transcriptional regulators are classified in families based on their functional and sequence 
similarities.  One such family is the TetR family of transcriptional regulators (36).  Members of 
the TetR family are two-domain proteins which possess an N-terminal HTH DNA-binding 
motif and a C-terminal ligand regulatory domain.  Many of these regulators control the 
expression of MDR efflux transporters that are required for bacteria to adapt to environmental 
stresses.  These transporters protect bacterial cells from deleterious compounds by actively 
extruding these compounds as they enter the cells. 
Understanding the action mechanisms of these efflux transporters and their 
transcriptional regulators is vital due to the potential that these proteins can offer for new drug 
targets.  Of all known multidrug efflux transporters, the E. coli AcrB multidrug efflux pump 
shows the widest substrate specificity, ranging from most of the currently used antibiotics, 
disinfectants, dyes, detergents, to simple solvents (39, 40).  Thus, AcrB offers one of the best 
systems to understand the broad chemical specificity of these transporters.  In Chapter 2 of this 
dissertation, we describe the crystal structures of four AcrB mutants.  These mutant proteins 
have allowed us to depict one of the transient conformational states of the transporter during 
the transport cycle. 
Chapter 3 concerns the drug-transporter interaction in the AcrB efflux transporter.  Our 
experimental results indicate that this transporter binds antimicrobials with dissociation 
constants in the micromolar region.  Remarkably, we observed that the AcrR transcriptional 
regulator, which modulates the expression of AcrB in E. coli, interacts with the same set of 
toxic chemical compounds as AcrB with strikingly similar affinities.  Chapter 4 demonstrates 
our study on how this regulator interacts with different antimicrobial agents. 
In Chapter 5  we switch our gear to elucidate the crystal structure of the Campylobacter 
jejuni CmeR transcriptional regulator, which controls the expression of the tripartite CmeABC 
RND-type multidrug resistant efflux transporter.  Our findings reveal novel structural features 
of this regulator and provide new insight into the mechanisms of ligand binding and CmeR 
regulation.  
Chapter 6 concerns the crystallization and preliminary x-ray diffraction analysis of the 
multidrug efflux transporter NorM from the pathogen N. gonorrhoeae.  NorM belongs to the 
most recently classified MATE family of transporters and recognizes a number of cationic and 
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neutral antimicrobial agents.  The crystallographic data potentially will allow us to produce the 
first structural model of this new transporter family. 
Chapter 7 describes the crystal structure of the CusB membrane fusion protein which 
associates with the inner membrane efflux transporter CusA and an outer membrane channel 
CusC to form the tripartite CusABC efflux complex in E. coli.  This RND-type efflux system 
specifically recognizes and confers resistance to Cu(I) and Ag(I) ions. 
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CHAPTER 2. Conformation of the AcrB Multidrug Efflux Pump in 
Mutants of the Putative Proton Relay Pathway 
 
A paper published in Journal of Bacteriology, 2006,  p. 7290-7296, Vol. 188, No. 20 
 
Chih-Chia Su, Ming Li, Ruoyu Gu, Yumiko Takatsuka, Gerry McDermott, Hiroshi 
Nikaido, and Edward W. Yu 
 
 
ABSTRACT 
 
 We previously reported the X-ray structures of wild-type Escherichia coli AcrB, a proton 
motive force-dependent multidrug efflux pump, and its N109A mutant. These structures 
presumably reflect the resting state of AcrB, which can bind drugs. After ligand binding, a 
proton may bind to an acidic residue(s) in the transmembrane domain, i.e., Asp407 or Asp408, 
within the putative network of electrostatically interacting residues, which also include Lys940 
and Thr978, and this may initiate a series of conformational changes that result in drug 
expulsion. Herein we report the X-ray structures of four AcrB mutants, the D407A, D408A, 
K940A, and T978A mutants, in which the structure of this tight electrostatic network is 
expected to become disrupted. These mutant proteins revealed remarkably similar 
conformations, which show striking differences from the previously known conformations of 
the wild-type protein. For example, the loop containing Phe386 and Phe388, which play a 
major role in the initial binding of substrates in the central cavity, becomes prominently 
extended into the center of the cavity, such that binding of large substrate molecules may 
become difficult. We believe that this new conformation may mimic, at least partially, one of 
the transient conformations of the transporter during the transport cycle. 
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INTRODUCTION 
 
The Escherichia coli AcrB multidrug efflux pump (10, 11) is a member of the resistance-
nodulation-division transporter family (18). It recognizes many structurally unrelated toxic 
compounds and actively engages to extrude them from cells. Its crystallographic structure was 
solved by Murakami et al. (13) in 2002. We previously reported the X-ray structures of AcrB in 
the presence of four different ligands (21, 22). The structures showed that these ligands bind to 
the wall of the extremely large central cavity in the transmembrane region of the pump. This 
binding presumably corresponds to the first step in the drug extrusion process, since drug 
molecules then have to pass through the periplasmic domain of AcrB and eventually reach the 
outer membrane channel TolC. A subsequent study of the efflux pump by crystallization of a 
mutant AcrB protein with an N109A mutation with five structurally diverse ligands (20) 
indicated that AcrB contains at least two distinct binding sites. These five ligands not only bind 
to various positions of the central cavity but also bind to residues lining the deep external 
depression formed by the C-terminal periplasmic domain.  
AcrB is a proton motive force-dependent multidrug efflux pump that functions via a 
drug/proton antiport mechanism (23). Coupled with the outward movement of drug 
molecules, protons have to flow inward (towards the cytoplasm) to energize the efflux 
process. AcrB contains two acidic residues, Asp407 and Asp408, in the transmembrane (TM) 
helix TM4 and one basic residue, Lys940, in TM10, and these three residues appear to 
constitute a salt-bridged (and/or hydrogen-bonded) network (13, 22) (Fig. 1). The presence of 
such residues often means that they play an important functional role, presumably in the 
translocation of protons. 
For MexB (a homolog of AcrB) of Pseudomonas aeruginosa, it has been shown that 
Asp407, Asp408, and Lys939 (corresponding to Asp407, Asp408, and Lys940 of AcrB) are 
indeed essential for transport function (7), and this Asp-Lys-Asp triad was also found to be 
essential in E. coli AcrB (14). Recently, we found that Thr978 of AcrB TM11, located close 
to the triad, is also essential for function (17); this residue may also be a component of the 
putative network of tightly interacting residues just mentioned (Fig. 1).  
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During the translocation of the ligand, active transporters must go through significant 
conformational changes, which are coupled to the expenditure of energy. With transporters 
that use ATP hydrolysis as an energy source, one can attempt to trap the transporter in one of 
the transient conformations by using vanadate-ADP (5, 16). However, similar approaches are 
not feasible with transporters such as AcrB, which is energized by proton motive force. We 
reasoned that proton translocation may perturb the salt bridge/H-bonding interactions within 
the D407-K940-T978-D408 complex and that this transient state of AcrB might be mimicked 
by replacing one of these residues with alanine, which cannot be protonated or deprotonated. 
We report here that the D407A, D408A, K940A, and T978A mutations cause remarkably 
similar and extensive alterations in the conformation of AcrB. 
MATERIALS AND METHODS  
 
Construction of D407A, D408A, K940A, and T978A mutants. Mutations were introduced 
by the method described in the accompanying paper (17). All of the mutant acrB genes 
contained a sequence coding for four additional histidine residues at the C terminus, and each 
of the proteins therefore had a hexahistidine sequence at the end (together with two histidine 
residues supplied by the native AcrB protein).  
Purification of AcrB. The mutant AcrB proteins were overproduced in E. coli BL21-
Gold(DE3) cells (Stratagene), using a plasmid derived from pSPORT1 (Invitrogen). Cells 
were grown in 6 liters of LB medium with 100 µg/ml ampicillin. Cells were disrupted with a 
French pressure cell. The membrane fraction was collected and washed twice with high-salt 
buffer containing 20 mM sodium phosphate (pH 7.2), 2 M KCl, 10% glycerol, 1 mM EDTA, 
and 1 mM phenylmethylsulfonyl fluoride and once with 20 mM HEPES-NaOH buffer (pH 
7.5) containing 1 mM phenylmethylsulfonyl fluoride. The membrane proteins were then 
solubilized in 1% n-dodecyl-ß-D-maltoside (wt/vol). Insoluble material was removed by 
ultracentrifugation at 370,000 x g. The extracted protein was purified with hydroxyapatite and 
Cu2+-affinity columns (23).  
11 
 
Crystallography. Crystals of the D407A, D408A, K940A, and T978A mutants were grown 
by hanging-drop vapor diffusion at 25°C. A protein solution containing 30 mg/ml mutant 
protein in 20 mM Tris (pH 7.5), 0.1% n-dodecyl-ß-D-maltoside, and 20 mM dithiothreitol was 
mixed with an equal volume of a reservoir solution containing 6.5 to 8.5% polyethylene 
glycol 3000, 8% glycerol, and 30 mM sodium citrate (pH 5.6) or 30 mM potassium citrate 
(pH 6.5). Crystals appeared in the drops within 4 days. Cryoprotection was achieved by 
raising the glycerol concentration stepwise to 35%, with a 5% increment at each step. The 
conditions used for crystallization were essentially identical to those used earlier for the wild-
type AcrB protein (22), except for the pH of the Tris buffer used. When the wild-type protein 
was crystallized under the conditions described here, a structure identical to that reported 
earlier was obtained (unpublished results).  
All X-ray intensity data sets were collected at the Advanced Light Source at 
Lawrence Berkeley National Laboratory (beamline 8.2.1) at a cryogenic temperature (100 K). 
The diffraction data were processed with DENZO and scaled with SCALEPACK (15). The 
crystals of the AcrB mutants took the R32 space group, with the unit cell dimensions listed in 
Table 1. Initially, the overall structures of the AcrB mutants were determined by molecular 
replacement, using the MolRep program (19) in the CCP4 package. The wild-type AcrB 
structure (Protein Data Bank no. 1OY6) was used as a search model. Before refinement, 5% 
of all data were set aside for cross-validation (2). The model refinements were performed 
using CNS (3) and CCP4 (4). Model rebuilding was conducted using the program O (8). 
Labeling of purified CL-F386C AcrBHis mutant proteins with MIANS and fluorescence 
measurements. The acrB gene was first modified by converting the codons for two intrinsic 
cysteines (Cys493 and Cys887) to those for serines by site-directed mutagenesis, producing 
cysteine-less (CL) AcrB; this mutant protein appeared to be fully functional in providing drug 
resistance, as reported earlier for proteins with alanine mutations of the same residues (6). 
Phe386 in CL AcrB was then converted to cysteine, and another mutation in the proton relay 
region was introduced, when necessary, in the same way. The purified CL-F386C AcrBHis 
proteins (3 to 4 mg/ml in 20 mM HEPES-KOH buffer containing 50 mM NaCl, 0.02% n-
dodecyl-ß-D-maltoside, and 10% glycerol [pH 7.5]) were diluted in the assay buffer (20 mM 
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HEPES-KOH [pH 7.5] containing 50 mM NaCl and 0.02% n-dodecyl-ß-D-maltoside) at a 
concentration of 0.5 µM (57 µg/ml). The reaction was initiated by the addition of 2-(4'-
maleimidylanilino)naphthalene 6-sulfonic acid sodium salt (MIANS; Molecular Probes) to a 
final concentration of 5 µM, and fluorescence was monitored continuously at room 
temperature with an RF-5301PC spectrofluorophotometer (Shimadzu) at an emission 
wavelength of 430 nm (excitation, 330 nm). A similar labeling experiment was also carried 
out by using 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin (CPM; Molecular 
Probes).  
Protein structure accession numbers. The coordinates for the protein structures have been 
deposited in the Protein Data Bank (PDB) under accession numbers 2HQC (D407A mutant), 
2HQD (D408A mutant), 2HQF (K940A mutant), and 2HQG (T978A mutant).  
RESULTS 
Crystallographic structures of mutants of the putative proton relay system. We solved the 
three-dimensional structures of the AcrB D407A, D408A, K940A, and T978A mutants by X-
ray crystallography through molecular replacement. The structures were determined with a 
maximum resolution of 3.38 to 3.65 Å. The overall Rwork values were between 25.1 and 27.1%, 
and Rfree values were between 27.5 and 30.3%. Refinement statistics are shown in Table 1. The 
overall structures of these mutant proteins were very similar to each other. Each mutant protein 
formed a homotrimer, with its threefold symmetry axis passing through the center of the trimer. 
Compared with wild-type AcrB, the mutant transporters showed some unique conformational 
changes, as described below.  
Short-range alterations. Electron density omit maps showed that some of the tight 
interactions among four residues, namely, Asp407, Asp408, Lys940, and Thr978 (Fig. 1), 
became profoundly disturbed in the mutants. As shown in Fig. 2 (top panel), in the wild-type 
protein the side chains of some of these residues show clearly interpretable electron densities, 
even at the modest overall resolution of our structures, presumably because they are 
immobilized by the strong electrostatic interactions between them. However, in the mutant 
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proteins (Fig. 2, bottom panel, shows the same region in the D408A mutant protein as an 
example), much less detail of the side chain density is seen, most likely because the tight 
interaction network was disturbed. 
This disorder in the network region, introduced by the mutations, apparently spreads 
into the neighboring regions. Thus, in all four mutants, extensive changes occur in the 
backbone atoms in the part of TM4 that is proximal to residue 407 (Fig. 3). Thus, the regular 
H-bonding interactions of the backbone NH and C O groups characteristic of the -helix 
(Fig. 3, left panel) become distorted or disrupted (the right panel of Fig. 3 shows the D407A 
mutant as an example; similar changes are also found in the other mutants), as also seen in the 
disappearance of regular helical structures in the upper part of TM4 in Fig. 4 (bottom panel), 
where the structure of the TM domain of the K940A mutant is given as an example. The 
disordering of the proximal part of TM4, as illustrated in Fig. 3, makes this segment longer, 
also creating a drastic change in the positions of residues of the loop between TM helices 3 
and 4 (noted by an arrow on the left in Fig. 5). This loop is located close to the ceiling of the 
central cavity, and the details, which could be established unequivocally because of the 
electron density of the phenyl groups in Phe386 and Phe388, are shown in Fig. 6B (panel A 
shows the electron density maps of the wild-type protein and the K940A mutant protein). 
Compared with the wild-type structure (Fig. 6B, left panel), the loops of all mutants, formed 
by residues 384 to 393 between TM3 and TM4, intrude prominently into the center of the 
cavity (Fig. 6B, right panel). The change includes residues Phe386 and Phe388 coming about 
6 to 7 Å closer to the center of the cavity, and thus also to their counterparts from the other 
subunits of the trimer. For example, the distances between the CZ carbon atoms of the phenyl 
groups of Phe386 and Phe386' in the D407A, D408A, K940A, and T978A mutants are 6.7 Å, 
6.0 Å, 6.2 Å, and 7.4 Å, respectively, in contrast to 16.2 Å in the wild-type protein. These 
three phenylalanines essentially decrease the size of the upper part of the central cavity by 
forming a septum-like structure (Fig. 6C), resulting in an opening of only about 6 Å in 
diameter at this region, in contrast to the nearly 20-Å-diameter opening in the wild-type 
protein. 
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Long-range alterations. The local changes were propagated to produce a number of 
remarkably extensive long-range alterations, as shown in Fig. 4. Thus, looking at the K940A 
mutant protein, the kinked TM helix 5 becomes disordered such that the helical structure 
before the kink totally disappears, and even the portion after the kink becomes strongly 
disordered. The following TM6 helix also becomes shortened. Furthermore, the helix 
connecting the N-terminal and C-terminal halves of the transmembrane domain, i.e., I  (13), 
again becomes drastically shortened. The TM helices of the C-terminal half (TM7 through 
TM12) do not undergo extensive disordering, except that helix 11 (containing Thr978) 
becomes somewhat shorter and the C-terminal end of helix 12 becomes disordered. All of 
these changes occur with remarkable regularity in all four mutants (K940A, D407A, D408A, 
and T978A). As part of this global conformational alteration, we found that the upper half of 
TM5 shifts upward about 2 Å, just like the corresponding part of TM4. Significant backbone 
movement was also found in the flexible loop, i.e., residues 29 to 32, above TM1 (the 
electron density map of this region is also shown in Fig. 6A, and the shift is highlighted with 
an arrow on the right in Fig. 5). This loop forms one side of the vestibule through which 
ligands are hypothesized to enter the central cavity (13, 21, 22). The displacement can be 
interpreted as a rotation of this portion of the loop, with the rotational axis passing through 
the C-  atoms of residues 28 and 32. The side chain of Leu30, which is at the center of this 
displaced region, appears to have been flipped about 100° from the central cavity. The 
rotation also shifts the locations of the C-  atoms of Leu30 and Pro31 about 5 Å away from 
their original positions. The movement of this region occurs in a direction opposite (that is, 
away from the cavity) from that of the nearby loop between TM3 and TM4 mentioned earlier 
(into the cavity).  
Many regions of the periplasmic domain are also altered. It is intriguing that the loop 
that forms the bottom and part of the "left" wall of the periplasmic drug binding site (20) is 
shifted significantly (indicated by an arrowhead in Fig. 5). The side chain of one of the 
residues that appear to be involved in ligand binding, Glu673 (see Fig. 5 in reference 20), is 
part of this shifted region, and in our model its side chain is moved away from the position of 
bound ligand about 6 Å in comparison with the position in the wild-type protein.  
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Accessibility of the loop between TM3 and TM4. The conformational alterations observed 
in the mutant AcrB proteins were extensive. Although the crystallization conditions were 
similar to those employed earlier (21, 22), we wanted noncrystallographic evidence to 
strengthen our conclusion that the region involving Phe386 and Phe388 is indeed altered 
strongly in its conformation in the mutant proteins. We therefore mutated the Phe386 residue 
to cysteine and examined the accessibility of this residue for modification with fluorescent 
maleimide reagents. As shown in Fig. 7, Cys386 mutant AcrB proteins containing additional 
mutations in the putative proton relay complex (D407A, D408A, K940A, and T978A) were 
modified by MIANS significantly more rapidly than the protein not containing any second 
mutation. Because the fluorophore of MIANS (anilinonaphthalene sulfate) is affected by its 
environment in terms of its fluorescence, we also used a coumarin maleimide (CPM), which 
is much less sensitive to its environment, and obtained similar results (not shown). These 
results suggest that the conformation of the region between TM3 and TM4 is indeed altered 
in the D407A, D408A, K940A, and T978A mutants. 
DISCUSSION 
In previously determined structures of AcrB, the side chains of Asp407, Asp408, Lys940, and 
Thr978 are close to each other and appear to form a salt bridge/hydrogen-bonding network 
(Fig. 1). It may be postulated that AcrB in this "resting-state" conformation is ready to bind 
substrates, as the central cavity of this conformer has indeed been shown to bind various drugs 
(22).  
As a working hypothesis, we assumed that the -amino group of Lys940 is protonated 
and the carboxyl groups of Asp407 and Asp408 are deprotonated, in view of their close 
proximity (17). During the process of proton translocation, one of the carboxyl groups, 
perhaps that of Asp407, can be postulated to become protonated. This is similar to what has 
been assumed for many active transporters energized by proton motive force (for example, 
see the case of the lactose permease LacY [1]). This protonation of an acidic residue is 
expected to disturb the tight salt bridge/hydrogen-bonding network of the four residues, 
distort the positions of these residues relative to each other, and initiate a series of 
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conformational changes that would result in the transport of drugs, as stated in the 
accompanying paper (17).  
We undertook this study on the assumption that disturbing the interactions among 
Asp407, Asp408, Lys940, and Thr978 might in some way mimic the consequences of 
protonation of one of the carboxyl residues. Indeed, we found that conversion of any of these 
residues to alanine produced a widespread conformational alteration (Fig. 3 to 6). It is also 
remarkable that mutation of any of the four residues produced nearly identical new 
conformations, suggesting that the trigger for change is the disruption of the same salt 
bridge/H-bonding network. Although it may be argued that the replacement of a charged 
residue with an uncharged Ala residue may disturb the protein structure simply because of the 
unfavorable thermodynamics of insertion of the remaining charged residues into the 
membrane, without any relation to H+ translocation, the same altered conformation in the 
T978A protein, where charged residues have not been altered, refutes this interpretation.  
The new conformation shows that the TM domains of the three protomers still form a 
large central cavity with a diameter of about 35 Å. However, the diameter of this central 
cavity decreases to about 6 Å in a region close to the ceiling due to the protrusion of the loop 
containing Phe386 and Phe388 (Fig. 6). This is the loop that forms a multidrug binding site in 
wild-type AcrB (22), but this region may become too tight to bind large drugs in these AcrB 
mutants. If we assume that the new conformation mimics one of the transient stages after the 
binding of drugs by resting-state AcrB, it may be that the conformational alteration induced 
by protonation pushes the drug molecules away from the initial site to a new position closer 
to the final stage of their expulsion. Drug binding studies, both biochemical and 
crystallographic, are obviously needed to follow up this hypothesis.  
Compared with the trimer of wild-type AcrB, there is an increase in intersubunit 
distance in the mutant homotrimers. For example, the distance between the top regions of 
TM1 and TM8' from adjacent subunits is increased about 2 Å in the K940A structure. This 
change opens the vestibule located above these TM helices some 3 Å. It also enlarges the 
bottom of the cavity opened to the cytoplasm by 2 Å. Similar changes were found in the other 
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mutant AcrB proteins. Anisotropic network model calculations (9) showed that the motion in 
the central cavity of AcrB is dominated by breathing vibrational modes. We suspect that the 
expansion of the AcrB mutants mimics this breathing motion.  
Our hope was that the conformation of the mutant proteins would give us not only a 
glimpse of the transitional states of the AcrB transporter during a normal cycle, but also hints 
on the pathway of drug molecules during export, especially within the periplasmic domain. 
However, alterations were not extensive in the conformation of the periplasmic domain (Fig. 
5), and the reasons for this outcome are not known. 
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Figures and Captions 
 
FIG. 1. Putative salt bridge/H-bonding network (D407-D408-K940-T978) in the wild-type 
AcrB protomer, based on PDB file 1IWG (15). The view is along the line perpendicular to the 
membrane surface, from the periplasmic side. In spite of the modest resolution of the overall 
structure, the electron densities of some side chains can be seen clearly (see Fig. 2, top panel). 
The stick model in this figure as well as that in Fig. 6B was produced by the program PyMol 
(W. L. Delano, PyMol Graphic System [www.pymol.org]). The locations and sizes of the cross 
sections of TM4, TM10, and TM11 shown are crude approximations added simply to aid 
understanding.  
iii 
TABLE 1. Data collection and crystallographic analysis of AcrB mutantsa 
Mutant 
Cell 
constants 
(Å) 
Resolution 
(Å) 
Completeness 
(%) 
Rsym 
(%) 
Rwork/Rfree 
(%) 
No. of reflections 1/
 
(I
) Total Unique
D407A 
mutant 
a = b = 
145.4, c 
= 514.5, 
= ß = 
90, = 
120 
3.56 
(3.78-
3.56) 
100 (94.7) 10.2 
(35.9)
27.1/29.4 1,086,717 41,936 3.9
 
D408A 
mutant 
a = b = 
145.0, c 
= 513.7, 
= ß = 
90, = 
120 
3.65 
(3.78-
3.65) 
94.7 (92.3) 10.6 
(46.5)
26.1/30.3 618,639 23,658 1.3
 
K940A 
mutant 
a = b = 
145.6, c 
= 519.7, 
= ß = 
90, = 
120 
3.38 
(3.56-
3.38) 
99.9 (99.0) 7.8 
(45.8)
25.1/28.0 880,107 43,054 1.4
 
T978A 
mutant 
a = b = 
144.9, c 
= 518.6, 
= ß = 
90, = 
120 
3.38 
(3.56-
3.38) 
99.1 (94.6) 9.3 
(49.1)
25.4/27.5 1,112,163 42,367 2.7
 
 
a
 All mutants belong to space group R32. Numbers in parentheses are for the highest-
resolution shells. 
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FIG. 2. Side view of the putative proton relay network involving TM4 and TM10. Electron 
density omit maps were calculated at 1 . (Top) In wild-type AcrB, some of the side chains 
are visible, presumably because of the strong electrostatic interactions among these residues. 
(Bottom) In contrast, in mutants (the D408A mutant is shown as an example), much less 
detail can be seen, presumably because of the weakening and abolition of the electrostatic 
interactions. 
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FIG. 3. Structure of the N-terminal portion of TM4. The view is from the side (in a direction 
parallel to the membrane surface). The hydrogen bonds (green dotted lines) were calculated 
by the program DeepView, and the picture was drawn by using DeepView and POV-ray. The 
wild-type structure (left) and the D407A mutant structure (right) were aligned for the best 
overall fit of the entire protein backbone by DeepView and then horizontally displaced for a 
better view. In the wild-type AcrB protein (left), the backbone NH of Asp407 is H-bonded to 
the backbone C O of Gly403, four residues back, as it should be in the regular -helical 
structure. However, in the D407A mutant AcrB protein (right), the corresponding NH of 
Ala407 appears to H-bond to the C O of not only Gly403 but also Leu404, distorting the 
helix. Further upward, the H-bonding interactions involving NH groups of Leu405, Leu404, 
and Gly403 in the wild-type protein are totally lost in the mutant protein. This distortion of 
the -helix extends the chain, such that the top of TM4 (near the top of the figure) becomes 
higher in position in the mutant protein by nearly 2 Å, as shown.  
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FIG. 4. Secondary structures in TM domains. The figure was drawn by using the Cn3D 
program (National Center for Biotechnology Information) after alignment of the three-
dimensional structures of the wild type (PDB file 1IWG) and the K940A mutant (this study) 
through the Vector Alignment Search Tool (12), available at the National Center for 
Biotechnology Information website. Note that the assignment of the secondary structure was 
done in a uniform manner by the Vector Alignment Search Tool program, independent of the 
annotations in the PDB files. The TM helices are numbered in the wild-type structure. 
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FIG. 5. Global conformation of AcrB protomers, showing the deviation of the K940A 
structure from the wild-type structure. The structures were aligned for the best global fit, 
using backbone atoms, by the Iterative Magic Fit feature of the DeepView program, and the 
mutant structure was colored in rainbow colors (with red showing the most deviation) by 
using the "color by RMS deviation" feature of the program, whereas the wild-type structure 
is shown in white. The structure is shown so that the helices on the right side correspond to 
the N-terminal ones (TM1 through TM6) and those on the left side correspond to the C-
terminal ones (TM7 through TM12). The structure is tilted slightly from the membrane 
perpendicular in order to show the loop between TM3 and TM4 more clearly. The shift of 
this loop between TM3 and TM4 is indicated by an arrow on the left, and that of the loop of 
residues 29 to 34 is shown by an arrow on the right. The shift of the loop at the bottom of the 
periplasmic ligand binding site (23) is indicated by an arrowhead. Red sections at the 
extreme left portion of the figure are an artifact caused by the absence of some residues in the 
wild-type structure. The drawing was done by using DeepView and POV-ray.  
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FIG. 6. Structure of the loop between TM3 and TM4. (A) Simulated annealing composite 
omit map of the K940A mutant contoured at 1.0 . The figure shows the locations of Phe386 
and Phe388 in the central cavity and of residues along the left side of the vestibule. (B) 
Models of the loop (residues 385 to 389) viewed along the threefold axis (perpendicular to 
the membrane surface) from the periplasmic side. The left panel shows the structure in wild-
type AcrB (from PDB file 1IWG) (15), and the right panel shows the structures in mutant 
AcrB proteins (D407A, green; K940A, mauve; and T978A, orange) overlaid on top of the 
wild-type structure (yellow). (C) Vertical slab (5 Å thick) of the AcrB trimer, showing the 
essential closure of the top portion of the central cavity by the loop between TM3 and TM4 
in the K940A mutant protein (right). The same slab of the wild-type trimer is shown on the 
left for comparison. The slice plane goes through the approximate center of the central cavity 
as well as through the Pro833 residue in protomer A and Thr145 in protomer B. The picture 
was generated by the Deep View program followed by POV-ray.  
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FIG. 7. Reaction of purified CL-F386C AcrBHis mutants with the fluorescence probe 
MIANS. MIANS labeling was carried out with 0.5 µM purified protein in 2 ml of 20 mM 
HEPES-KOH (pH 7.5)-50 mM NaCl-0.02% dodecyl maltoside. Reactions were initiated by 
the addition of MIANS to a final concentration of 5 µM, and the fluorescence increase was 
recorded continuously at 430 nm (excitation, 330 nm). Mutants were as follows: 1, CL-
F386C; 2, CL386-N109A; 3, CL386-D407A; 4, CL386-D408A; 5, CL386-K940A; and 6, 
CL386-T978A. 
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CHAPTER 3. Ligand-transporter interaction in the AcrB multidrug efflux 
pump determined by fluorescence polarization assay 
 
A paper published in FEBS Letters Volume 581, Issue 25, 16 October 2007, Pages 4972-4976 
 
Chih-Chia Su and Edward W. Yu 
Abstract 
The AcrB of Escherichia coli pumps out a wide range of compounds, including most 
of the currently available antibiotics, and contributes significantly to the serious problem of 
multidrug resistance of pathogenic bacteria. Quantitative analysis of drug efflux by this pump 
requires the measurement of the affinity of ligands. Yet there has been no success in 
determining these values. We introduce here an approach of steady-state fluorescence 
polarization to study the interactions between four different ligands and the purified AcrB 
transporter in a detergent environment. Our assays indicate that the transporter binds these 
drugs with KD values ranging from 5.5 to 74.1 µM. 
29 
 
 
1. Introduction 
 
The emergence of multidrug-resistant pathogenic bacteria is a major current problem in public 
health. In gram-negative bacteria, much of the multidrug resistance phenotype is caused by the 
increased expression of multidrug efflux pumps. These pumps fall into several families, small 
multidrug resistance (SMR), major facilitator superfamily (MFS), multidrug and toxic 
compound extrusion (MATE), and resistance-nodulation-division (RND). The members of the 
RND superfamily [1] pump out the widest range of compounds, and are usually the major 
contributor to both the intrinsic antibiotic resistance, and when overexpressed, the increased 
resistance levels of multidrug resistant strains [2], as was recognized already in 1993 [3] and 
1994 [4]. However, quantitative analysis of the function of RND efflux pumps could not even 
be attempted during the last 14 years, because all attempts to measure the kinetic constants of 
the pump resulted in failure. 
 We here use a relatively simple methodology to quantitatively monitor interaction 
between a membrane protein, which in this study is the AcrB multidrug efflux pump of 
Escherichia coli [5], and its fluorescent ligands in detergent solution. Binding of a 
fluorescent ligand to a protein causes a decrease in rotational motion due to an increase in the 
size of the protein–ligand complex as compared to that of the free ligand, and thus results in 
increases in the polarization of fluorescence of the bound ligand. Fluorescence polarization is 
defined as 
                                                       P=(I -I )/(I +I ) 
 
where P is the observed polarization, and I  and I  represent the intensity of emissions 
parallel and perpendicular to the incident polarized light. 
AcrB [5] is a prototypical member of the RND family of transporters [1]. It 
recognizes many structurally unrelated compounds, including most of the currently available 
antibiotics and chemotherapeutic agents, detergents, dyes, and simple solvents, and actively 
engages to extrude them from cells [6]. This inner membrane efflux pump interacts with a 
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periplasmic membrane fusion protein, AcrA [7], and an outer membrane channel, TolC [8], 
to mediate the extrusion of toxic compounds directly into the external medium, across both 
membranes of E. coli. 
The structure of AcrB has been studied extensively [9], [10], [11], [12], [13], [14], 
[15] and [16]. Using the purified AcrB multidrug efflux pump, we succeeded for the first 
time in determining the affinity of ligands for the pump, and further in demonstrating the 
competition between ligands for the binding process. This study will be the first step for the 
quantitative analysis of the kinetics of the most important class of multidrug efflux pumps in 
gram-negative bacteria. 
2. Materials and methods 
2.1. Purification of AcrB 
The AcrB protein that contains a 4×His tag at the C-terminus was overproduced in E. coli 
BL21-Gold (DE3) cells (Stratagene) using the plasmid derived from pSPORT1 (Invitrogen) 
[17]. Cells were grown in 6 L of LB medium with 100 µg/ml ampicillin. Cells were disrupted 
with a French pressure cell. The membrane fraction was collected and washed twice with 
high salt buffer containing 20 mM sodium phosphate (pH 7.2), 2 M KCl, 10% glycerol, 
1 mM EDTA and 1 mM phenylmethanesulfonyl fluoride (PMSF), and once with 20 mM 
HEPES–NaOH buffer (pH 7.5) containing 1 mM PMSF. The membrane proteins were then 
solubilized in 1% (w/v) n-dodecyl-β-d-maltoside (DDM). Insoluble material was removed by 
ultracentrifugation at 370 000 × g. The extracted protein was purified with hydroxyapatite, 
Cu2+-affinity and G-200 sizing columns [10] and [18]. 
2.2. Fluorescence polarization assays 
Fluorescence polarization assays [19] and [20] were used to determine the drug binding 
affinities of AcrB. The experiments were done using a ligand binding solution containing 
20 mM Tris (pH 7.5), 0.05% DDM, and 1 µM ligand [rhodamine 6G (R6G), ethidium (Et), 
proflavin (Pf), or ciprofloxacin (Cip)]. The AcrB protein solution in 20 mM Tris (pH 7.5), 
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0.05% DDM, and 1 µM ligand was titrated into the ligand binding solution until the 
polarization (P) became unchanged. In this assay, the protein–drug interaction would reach 
equilibrium within 1 min. As this is a steady-state approach, fluorescence polarization 
measurement was taken after incubation for 5 min for each corresponding concentrations of 
the protein and drug to ensure that the binding has reached equilibrium. It should be noted 
that the detergent concentration was kept constant at all times to eliminate the change in 
polarization generated by drug–DDM micelle interaction. All measurements were performed 
at 25 °C using a PerkinElmer LS55 spectrofluorometer equipped with a Hamamatsu R928 
photomultiplier. The excitation wavelengths were 527, 483, 447, and 330 nm, respectively, 
for R6G, Et, Pf, and Cip. Fluorescence polarization signals (in ∆P) were measured at 
emission wavelengths of 550, 620, 508, and 415 nm, respectively, for these ligands. Each 
titration point recorded was an average of 15 measurements. Data were analyzed using the 
equation, P={(Pbound-Pfree)[protein]/(KD+[protein])}+Pfree, where P is the polarization 
measured at a given total protein concentration, Pfree is the initial polarization of free ligand, 
Pbound is the maximum polarization of specifically bound ligand, and [protein] is the protein 
concentration. The titration experiments were repeated for three times to obtained the 
average KD value. Curve fitting was accomplished using the program ORIGIN [21]. 
3. Results 
3.1. Binding affinities of various AcrB ligands 
The goal of this research was to determine the binding affinities of a variety of 
ligands to AcrB. Fluorescence polarization based-assay was initially carried out to study the 
interaction between AcrB and R6G. (Fig. 1a) illustrates the binding isotherm of AcrB in the 
presence of 1 µM R6G. As presented in the figure, a simple hyperbolic curve was observed 
with the KD of 5.5 ± 0.9 µM. The Hill plot of the data (Fig. 1b) yields a Hill coefficient of 1, 
suggesting a simple drug binding process with no cooperativity. 
Fluorescence polarization was also used to observe the binding of Et, Pf and Cip to 
the transporter. In comparison with R6G, other ligands tested show somewhat lower affinity. 
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Thus, Et bound with a KD of 8.7 ± 1.9 µM (Fig. 2a), Pf with that of 14.5 ± 1.1 µM (Fig. 2b), 
and Cip with that of 74.1 ± 2.6 µM (Fig. 2c). 
3.2. Binding of two drugs by AcrB 
We carried out several titration experiments that involved the initial saturation of 
AcrB with 100 µM of Et. To ensure that AcrB and Et formed a complex, the mixture was 
incubated for at least 2 h before titrating with 1.5 µM Pf. Fluorescence polarization 
experiments indicated that AcrB-Et binds Pf with a KD of 61.0 ± 0.9 µM (Fig. 3). This value 
is about four times of the KD of Pf (14.5 ± 1.1 µM) in the absence of Et, indicating that Et 
interferes with the binding of Pf to AcrB, possibly because the two compounds compete with 
each other for the same binding site. 
We carried out similar titration experiments with the pre-formed AcrB–Et complex 
using 1.5 µM Cip. The results gave a KD value of 70.4 ± 15.4 µM for Cip (data not shown), 
which is not significantly different from the KD of Cip (74.1 ± 2.6 µM) determined in the 
absence of Et. Although it is tempting to conclude that Et and Cip bind to non-overlapping 
sites, the numerical precision of KD values is not high in this case because of the quite low 
affinity of this ligand, and we believe that further experiments utilizing different approaches 
are needed in this case. 
3.3. pH dependence of drug binding to AcrB 
We performed fluorescence polarization experiments to determine the binding of 
R6G to AcrB at different pH values. Fig. 4 illustrates the decrease in KD values for 
rhodamine 6G as the pH increases from 5.5 to 8.4. 
3.4. Detergent concentration does not affect drug binding to AcrB 
To analyze if the detergent concentration affects the fluorescence polarization results, 
we measured the dissociation constant of the AcrB–R6G complex in different concentrations 
of detergent, DDM. We found that at moderate detergent concentrations, the concentration of 
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detergent does not have much influence on the results. At 0.5%, 0.05%, and 0.005% DDM, 
the dissociation constants of the AcrB–R6G complex were 7.2 ± 0.1, 5.5 ± 0.9, and 
4.4 ± 0.8 µM, respectively. 
4. Discussion 
We demonstrated that the technique of fluorescence polarization is sensitive and 
precise enough to detect ligand binding of E. coli AcrB, an intrinsic membrane protein in a 
detergent environment. As this is a steady-state approach, it is important to ensure that the 
binding equilibrium has reached before data collection. A stop-flow study of an oligopeptide 
OppA transporter, belonging to the ABC superfamily, indicated that peptide binding to OppA 
would reach equilibrium within 20 ms when the concentrations of the protein and peptide are 
in the micromolar range [22]. Thus, a 5 min period for incubation in our experiments should 
be more than enough to allow the binding to reach equilibrium. We obtained results showing 
that the ligands bind to AcrB with their KD values between 5.5 (R6G) and 74.1 µM (Cip) 
(Fig. 1 and Fig. 2). These values are similar to the KD for most substrates for the MdfA (a 
MFS transporter) [23] and EmrE (a SMR transporter) [24] multidrug pumps, determined by 
competition with tetraphenylphosphonium binding. Although our data suggested the binding 
stoichiometry of 1:1 monomeric AcrB-to-drug molar ratio, there is a formal possibility that 
any compound may bind to more than one site on the protein with similar affinity that could 
not be discriminated using this technique. Thus, further experiments utilizing different 
approaches are needed to confirm this drug binding stoichiometry. 
One of the main goals of our work is to introduce a relatively simple approach to 
study membrane protein–ligand interaction in a detergent environment. It should be note that 
detergent solubilized protein in detergent micelles may behave differently from that 
reconstituted in a lipid environment, including altering the binding affinity of drugs to AcrB 
in this case. However, a study of the EmrE transporter suggested that EmrE binds drugs with 
similar strengths in different membrane mimetic environments, including those in DDM 
micelles and in reconstituted lipid vesicles [25]. The observed dissociation constants were in 
the micromolar range for the EmrE drugs in any of the membrane mimetic environments 
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[25]. Detailed study of AcrB–ligand interaction in the lipid environment would be necessary 
to determine whether the reconstituted AcrB behaves differently in terms of drug binding 
affinity. 
As our fluorescence polarization assay was performed in a detergent environment, we 
aware of the fact that detergent micelles in solution may have interaction with the drug 
molecules. To eliminate this “non-specific” binding component that may cause an error for 
the measurement of drug binding affinity, it is important to keep the detergent concentration 
constant during titrations. It has been reported that the dissociation constants of DDM micelle 
with Et and Pf are 5.2 and 17.1 mM, respectively [25]. We measured the binding affinities of 
DDM micelle with R6G and Cip using fluorescence polarization assay (data not shown). We 
found that the interactions between the micelles and drugs are quite weak. Thus, we could 
only estimate these KD values, which were 2.9 mM for R6G–DDM micelle and 899.7 mM 
for Cip–DDM micelle, respectively. Apparently, the drug–DDM micelle interactions are in 
the millimolar range, which are about three orders of magnitude weaker than those of the 
drug–transporter interactions. 
We also examined the question of simultaneous binding of two different drugs to 
AcrB, by using fluorescence polarization assays. Et was a convenient ligand because it 
absorbs and emits light at very long wavelengths, far away from the wavelengths used by 
other dyes. Titrations of Pf into Et-saturated AcrB yielded a much increased dissociation 
constant compared with that in the absence of Et, suggesting strongly that both drugs bind in 
a competitive manner to an overlapping binding site in AcrB. 
To confirm that two drugs compete with one another for a specific binding site in the 
protein, we performed competition experiments in which tetraphenylphosphonium chloride 
(TPP) was titrated into a solution containing the preformed AcrB–R6G complex. In this case, 
TPP was chosen as a second ligand to knock off the bound R6G from AcrB. The absorption 
spectra of TPP (from 200 to 600 nm) showed that this molecule absorbs light at the 
wavelengths of 224.9, 268.0 and 275.9 nm. At λ = 527 nm, which is the excitation 
wavelength for R6G, the energy is too low to excite TPP. Thus, TPP was treated as a non-
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fluorescent ligand in the “knock off” experiments. The data revealed that TPP was able to 
bind AcrB and replace the bound R6G molecule from the protein as demonstrated by the 
release of R6G that resulted in the reduction of polarization (Fig. 5). This binding assay 
provides direct evidence that TPP interferes with the binding of R6G. However, it is not 
known that this heterologous displacement is due to a truly competitive binding or via 
negative heterotropic allostery between distinct binding sites of the ligands. We were unable 
to determine the binding affinity of TPP through these competition experiments due to 
precipitation of the protein at higher TPP concentrations. Regardless, the titrations 
demonstrate that R6G is bound specifically in the AcrB transporter. 
We also tried these competition experiments using erythromycin, which is another 
AcrB drug, as a second ligand to replace the bound R6G from the transporter (not shown). 
The data revealed that erythromycin is not capable of knocking off the bound R6G, as the 
polarization of R6G does not change during titrations. Thus, there is a chance that different 
class of drugs may bind at different sites in AcrB. 
The binding of R6G to AcrB was strongly pH-dependent. A trivial explanation of this 
result was the pH-dependent alteration of charge state in the ligand. However, we found that 
there is essentially no change in the emission spectra of free R6G in the pH range examined 
in Fig. 4, suggesting that the electronic arrangement of the protonated and de-protonated 
states of R6G are very similar. The pKa of R6G is nearly neutral, with the value equals 7.5 
[26] (the pKas of Pf and Cip are 8.1 and 6.1, respectively [27]). At pH < pKa, R6G should 
exist in its protonated form. When pH > pKa, this dye should be predominantly unionized. It 
is expected that R6G should bind tighter to the transporter at acidic pH, as it is predominantly 
in the positively charged form. However, the reverse case is seen from the pH dependent 
data. One possible explanation is that R6G possesses a large degree of delocalization. It is 
this large extent of electron delocalization that makes the chemical properties of the 
protonated and de-protonated forms of R6G very similar. Indeed, it has been reported that the 
observed octane/water partition coefficient of R6G remains the same from pH 4 to 11 
because of this charge delocalization phenomenon [26]. 
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Judging from the binding isotherms of AcrB in the presence of 1 µM R6G, these 
curves maintained the simple hyperbolic shape and reached saturation at the same AcrB 
concentration at different pH values (as shown in Fig. 1a). Thus, it is not likely that altering 
the pH affects the capacity of binding. Perhaps the pH effect is related to the protonation 
state of acidic residues in the binding pocket: there are several acidic residues in the ligand 
binding site of the asymmetric AcrB crystal [12], with Asp276 particularly close to the 
ligand. The strong pH dependence for drug binding has been observed as the result of 
binding of cationic drugs with the glutamate residue in the EmrE multidrug transporter [24]. 
Alternatively, it could involve global conformational changes of the transporter that utilizes 
the transmembrane electrochemical gradient of protons for activity. 
Fluorescence polarization assay has been widely used for studying protein–DNA 
interactions [19], [20], [28] and [29], and lately for determining affinities of drug binding in 
transcriptional regulators [29], [30] and [31]. To our knowledge, this is the first attempt using 
this methodology to investigate interaction between membrane protein and bound drug. The 
availability of fluorescence polarization to measure affinities of a variety of AcrB substrates 
will provide the means for studying the interactions of other purified transporters with their 
substrates in detergent solutions. 
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Figures and Captions 
 
Fig. 1. Representative fluorescence polarization of AcrB in 0.05% DDM with R6G. (a) 
Binding isotherm of AcrB with R6G, showing a KD of 5.5 ± 0.9 µM, in buffer containing 
20 mM Tris (pH 7.5) and 0.05% DDM. (b) Hill plot of the data obtained for R6G binding to 
AcrB. α corresponds to the fraction of bound R6G. The plot gives a slope of 1.12 ± 0.02, 
indicating a simple binding process with a stoichoimetry of one AcrB protomer per one drug 
molecule. The interception of the plot provides a KD of 5.4 ± 1.0 µM for the R6G binding. 
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Fig. 2 
Fig. 2.Fluorescence polarization of AcrB with Et, Pf and Cip. Binding isotherms of AcrB 
with (a) Et, showing a KD of 8.7 ± 1.9 µM, (b) Pf, showing a KD of 14.5 ± 1.1 µM, and (c) 
Cip, showing a KD of 74.1 ± 2.6 µM. 
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Fig. 3.Binding of ligands by AcrB in the presence of 100µM of Et as determined by 
fluorescence polarization assay. The change in fluorescence polarization signals (∆FP) of Pf 
was measured at an emission wavelength of 508 nm. The binding curve suggests a KD of 61.0 
±0.9 µM for Pf. 
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Fig. 4.Effect of pH on the KD of R6G binding to AcrB. The resulting KDs were plotted 
against pH. 
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Fig. 5.AcrB binding competition experiment between R6G and TPP. AcrB (10µM) was pre-
incubated with R6G (1µM) for 2h before titration. The change in fluorescence polarization 
signals (∆FP) of R6G was measured at an emission wavelength of 550nm. TPP was non-
fluorescent in the experimental conditions. The decrease in ∆FP showed that the bound R6G 
was knocked off by TPP. 
45 
 
 
CHAPTER 4. Characterization of the multidrug efflux regulator AcrR from 
Escherichia coli 
 
A paper published in Biochemical and Biophysical Research Communications 
Volume 361, Issue 1, 14 September 2007, Pages 85-90 
 
 
Chih-Chia Su, Denae J. Rutherford and Edward W. Yu 
 
Abstract 
The Escherichia coli AcrR represses transcription of the acrB gene, which encodes 
the multidrug efflux pump AcrB that extrudes a wide variety of toxic compounds, by binding 
its target operator DNA. Fluorescence polarization was performed using purified, 
recombinant AcrR that contains a 6xHis tag at the C-terminus and a fluorescein-labeled 28-
base pair oligonucleotide bearing a predicted palindrome (IR) operator sequence. Binding of 
AcrR to the predicted IR sequence occurred with a dissociation constant (KD) in the 
nanomolar range. Fluorescence polarization assays were also applied to characterize the 
affinity and specificity of AcrR interaction with three different fluorescent ligands, 
rhodamine 6G, ethidium, and proflavin. The KD values for these ligands range from 4.2 to 
10.1 µM, suggesting that AcrR is capable of recognizing a wide range of structurally 
dissimilar toxic compounds as it is in the case of the AcrB multidrug efflux pump. We found 
that the binding of rhodamine 6G to AcrR is inhibited by the presence of ethidium. In 
contrast, the dissociation constant of proflavin binding to AcrR was not affected by ethidium, 
a result suggesting that ethidium and proflavin are bound to distinct binding sites. 
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Introduction 
The increase in bacterial resistance to multiple drugs has emerged as a major clinical 
problem. One important mechanism that gives rise to multidrug resistance (MDR) in bacteria 
is the expression of multidrug transporters that are often regulated at the transcriptional level 
by transcriptional regulators [1]. Many of these transcriptional regulators are multi-drug 
binding proteins, which recognize the same array of toxic chemicals extruded by the 
transporters that they regulate [2]. These regulators often act as cytosolic chemical sensors 
and respond to threatening levels of toxic chemicals. The results are the over-expression of 
MDR transporters, which, in turn, promote efflux from cells, thus protecting them from toxic 
substances. 
Bacterial efflux transporters capable of transporting multiple toxic compounds fall 
into five classes: (i) the ATP-binding cassette (ABC) family [3]; (ii) the major facilitator 
superfamily (MFS) [4] and [5]; (iii) the resistance-nodulation-division (RND) family [6] and 
[7]; (iv) the small multidrug resistance (SMR) family [8]; and (v) the multidrug and toxic 
compound extrusion (MATE) family [9]. The ABC family transporters take the free energy 
generated from ATP hydrolysis to expel toxic substances out of cells [10]. Efflux transporters 
in the other families, however, utilize the transmembrane electrochemical gradient of protons 
or sodium ions to extrude these harmful substrates from cells [10]. 
Of all known MDR transporters, the Escherichia coli AcrB multidug efflux pump, 
which belongs to the RND family, shows the widest substrate specificity ranging from most 
of the current use antibiotics, disinfectants, dyes, bile salts, fatty acids, and detergents, to 
simple solvents [11]. AcrB is regulated by a global transcriptional activator MarA and a local 
transcriptional repressor AcrR [12]. The acrR gene is located 141 bp upstream of the acrAB 
operon and transcribed divergently [12]. It encodes a 215-amino-acid protein, which shares 
N-terminal sequence and structural similarities to members of the TetR family of 
transcriptional repressors [13]. Like other members in the TetR family, the N-terminal 
domain of AcrR contains a predicted DNA-binding helix-turn-helix (HTH) motif, while its 
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C-terminal domain has unique sequences and is expected to form a multi-drug binding site 
for its inducing drugs. 
As a member of the TetR family of transcriptional regulators, it is expected that 
binding of drug to the C-terminal ligand-binding domain of AcrR triggers conformational 
change in its N-terminal DNA-binding region. This change in conformation results in the 
release of AcrR from its operator DNA, and thus allows transcription from its cognate 
promoter. 
At present, the AcrR palindrome (IR) operator site has not been identified. However, 
there is strong evidence that this IR is composed of a 24 bp sequence, 
5′TACATACATTTGTGAATGTATGTA3′. Ma et al. [12] demonstrated that AcrR 
interacts with the acr promoter located in the section between acrR and acrAB. A 
comparison of nucleotide sequences upstream of multidrug resistance transport genes also 
predicted that the upstream region of the acrAB operon contains a candidate IR operator. 
This operator consists of an inverting 24 bp sequence, which is well conserved and overlaps 
with the acrAB promoter [14]. 
In this study, we used fluorescence polarization assay [15], [16] and [17] to examine 
interaction between AcrR and its predicted target DNA. We also used this method to 
determine the affinities of three different AcrR drugs, ethidium (Et), proflavin (Pf), and 
rhodamine 6G (R6G). So far, all known members of the TetR family have been reported to 
bind target DNAs in the form of homodimers as basic units [13]. Thus, the DNA-binding 
data were fitted using an AcrR dimer as a fundamental unit. For drug binding, we fitted these 
data using a monomeric AcrR as a single structural unit since many of the TetR family 
members bind ligands in both subunits of the homodimers, although QacR only binds one 
drug molecule in the dimer [18]. The possibility of simultaneous binding of two different 
drugs by AcrR was also examined using this fluorescence polarization technique. 
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Results 
DNA binding 
Presumably, AcrR suppresses the expression of the AcrB multidrug efflux pump by 
binding its target DNA. As mentioned above, the predicted IR operator of AcrR is composed 
of an inverting 24 bp sequence. Fluorescence polarization-based assay was carried out to 
study the interaction between AcrR and a 28 bp DNA containing the IR sequence. Fig. 1A 
illustrates the binding isotherm of AcrR in the presence of 1 nM fluoresceinated DNA. The 
titration experiment indicated that AcrR binds the 28 bp operator, with a dissociation 
constant, KD, of 20.2 ± 1.4 nM. This value is substantially lower than those of the CmeR 
(KD = 88 nM) [19] and EthR (KD = 146 nM) [20] repressors, but albeit higher than the values 
of TetR (KD = 0.2 nM) [21], MtrR (KD = 0.9 nM) [17], and QacR (KD = 5.7 nM) [17] in the 
TetR family. It should be noted that this KD is sensitive to the concentration of salts in 
titration buffers, and in some cases also the length of oligodeoxynucleotides. Doubling the 
salt concentration may increase the KD by two orders of magnitude as shown in MtrR [17]. 
A Hill plot of the DNA-binding data yielded a Hill coefficient of 2 (Fig. 1B), 
suggesting a stoichiometry of two AcrR dimers per cognate DNA. The corresponding 
Scatchard plot showed a typical convex curve (see Suppl. Fig. S1), a result suggesting that 
more than one dimer of AcrR bind cooperatively to the DNA. To confirm the stoichiometry 
of AcrR and DNA binding, the protein was titrated into the binding buffer (containing 
500 nM fluoresceinated DNA) until the concentration of AcrR (as dimer) reached 1500 nM 
(Fig. 1C). The result indicated that the inflection point occurs at a dimeric AcrR 
concentration of 1000 nM, suggesting a stoichiometry of two dimers of AcrR per cognate 
DNA. 
Binding of AcrR ligands 
The goal of this experiment was to determine the binding affinities of a variety of 
AcrR ligands. We initially measured the binding affinity of Et by AcrR. Fluorescence 
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polarization measurements showed that the KD of the AcrR–Et complex is 4.2 ± 0.3 µM (Fig. 
2A). The Hill and Scatchard plots of the data (Fig. 2B and C) suggested that the protein 
employs a simple binding stoichiometry of 1:1 monomeric AcrR to Et molar ratio. 
Fluorescence polarization was also used to observe the Pf and R6G binding (Fig. 3). 
The values of KD were found to be 10.1 ± 0.8 µM and 10.7 ± 1.4 µM, respectively. QacR binds 
Et, Pf, and R6G with KD values of 186, 42, and 0.8 µM, respectively [22]. Thus, AcrR appears 
to have stronger interaction with Et and Pf, but weaker with R6G. 
Evidence of simultaneous binding of two drugs by AcrR 
It has been shown that two different drugs bind simultaneously to two different sites 
in a large binding pocket of the QacR regulatory protein [22]. This raises the question 
whether AcrR can accommodate two different drugs at a time. We carried out a series of 
titration experiments that involved the initial saturation of AcrR with 100 µM of Et. To 
ensure that AcrR and Et formed a complex, the mixture of AcrR and Et was incubated for at 
least two hours before titration. The pre-formed AcrR–Et complex was then titrated with 
1 µM of Pf. Fluorescence polarization assay was used to monitor the change in polarization 
of Pf. By using this method, we were able to provide evidence for the simultaneous binding 
of two drugs by AcrR. The polarization experiments indicated that AcrR binds Pf, with a KD 
of 14.9 ± 0.9 µM, in the presence of 100 µM Et. Fig. 4A depicts the binding isotherm of the 
AcrR–Et complex in titrating with Pf. This value is very close to the KD of Pf 
(10.1 ± 0.8 µM) in the absence of Et, indicating that the pre-bound Et does not affect the 
binding of Pf to the regulator. 
We also studied the binding of R6G in the presence of 100 µM Et using the same 
method. Fluorescence polarization experiments indicated that AcrR–Et binds R6G with a KD 
of 132.0 ± 9.1 µM (Fig. 4B). This KD is about 13 times of that of R6G in the absence of Et, 
suggesting the presence of Et severely interferes with the binding of R6G in AcrR. 
  
50 
 
 
Discussion 
Using recombinant AcrR protein that contains a 6xHis tag at the C-terminus, we 
confirmed that AcrR interacts with the 28 bp DNA, 
5′TTTACATACATTTGTGAATGTATGTACC3′. This DNA contains the inverting 24 bp 
IR. IR is a typical DNA sequence that forms binding sites for regulatory proteins in the 
promoter regions. A gel mobility shift assay, using a DNA fragment bearing the sequence of 
the promoter region between acrR and acrAB, has demonstrated that AcrR binds to the 
promoter sequence. Thus, our experimental data strongly suggest that this predicted 24 bp IR, 
located at the promoter region of acrR–acrAB, is very likely to serve as the acr operator. 
The affinity of AcrR for IR is in the nanomolar range (20.2 nM), and this dissociation 
constant is closer to that of QacR among members of the TetR family. The IR sequence of 
AcrR is similar in length to that of the long 28 bp IR1 recognized by QacR, but is different 
from the 15 bp tetO bound by TetR. TetR binds as a single dimer to the tetO operator [23], 
however, two dimers of QacR interact with one IR1 [24]. Based on the length of the IR 
sequence, we reasoned that AcrR might bind its operator as two homodimers in a way that is 
similar to the QacR–DNA binding. Our fluorescence polarization measurements suggested 
that two AcrR dimers interact with one 28 bp IR. Thus, it is very likely that two homodimers 
of AcrR bind the 24 bp target DNA cooperatively as shown in the structure of the QacR–
DNA complex [24]. 
The affinities of AcrR to its drugs are in the micromolar region, and the dissociation 
constants are quite similar to those of QacR [25], BmrR [26], and TtgV [27]. Based on the 
fluorescence polarization assays, titrations of AcrR to the ligand-binding solutions give a 
stoichiometry of 1:1 monomeric AcrR-to-drug molar ratio. As the recent preliminary X-ray 
diffraction data suggest a dimeric assembly of the AcrR regulator [28], thus we believe that 
each C-terminal ligand-binding site of AcrR (each subunit of which contains one site) in the 
homodimer binds a drug molecule. This drug-binding mode is the same as that of TetR [29], 
but different from the ligand-binding mode of QacR which binds one drug molecule per 
homodimer [22]. In comparing the DNA and drug-binding modes of AcrR with those of 
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TetR and QacR, AcrR is distinct in that its DNA-binding mode is similar to that of QacR, 
however, it employs the mode of drug-binding similar to that of TetR. Thus, the induction 
mechanism of AcrR may have unique features that have not been revealed by previous 
studies concerning other regulators in the TetR family. 
To address the question whether AcrR allows simultaneous binding of two different 
drugs, we used a ligand-binding assay that utilizes the polarization of fluorescence. Our 
experimental results suggest that AcrR is most likely to bind Et and R6G competitively as the 
binding affinity of R6G is greatly decreased in the presence of Et. In the case of Et and Pf, Pf 
is bound by both apo-AcrR and AcrR–Et in equal affinity, indicating that Et and Pf may 
exhibit noncompetitive binding. If this is the case, it is anticipated that Et and Pf are bound to 
distinct and unoverlapped binding sites in the regulator. Indeed, a docking study using the 
most recent crystal structure of apo-AcrR determined in our laboratory suggests that Et and 
Pf bind independently at different places in the large multi-drug binding pocket of AcrR (see 
Suppl. Fig. S4). This simultaneous drug-binding phenomenon has been found in the MdfA 
transporter [30] and the recent study QacR repressor [22]. Thus, it is not surprising that AcrR 
is capable of accommodating two different drugs at a time. 
Materials and methods 
Expression and purification of recombinant AcrR. The cloning, expression, and 
purification of recombinant AcrR that contains a 6xHis tag at the C-terminus were done as 
described before [28]. The purified 6xHis AcrR protein was extensively dialyzed against 
buffer containing 10 mM Na-phosphate (pH 7.2) and 100 mM NaCl, and concentrated to 
10 mg/ml. 
Fluorescence polarization assay for the DNA-binding affinity. Fluorescence 
polarization assays were used to determine the DNA-binding affinities of the AcrR regulator. 
Both the 28 bp oligodeoxynucleotide and fluorescein-labeled oligodeoxynucleotide were 
purchased from IDT, Inc. (Coralville, IA). These oligodeoxynucleotides contain the predicted 
24 bp IR site for AcrR binding. Their sequences were 5′-
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TTTACATACATTTGTGAATGTATGTACC-3′ and 5′-F-
GGTACATACATTCACAAATGTATGTAAA-3′, where F denotes the fluorescein which 
was covalently attached to the 5′ end of the oligodeoxynucleotide by a hexamethylene linker. 
The 28 bp fluoresceinated ds-DNA was prepared by annealing these two 
oligodeoxynucleotides together. Fluorescence polarization experiment was done using a 
DNA-binding solution containing 10 mM Na-phosphate (pH 7.2), 100 mM NaCl, 1 nM 
fluoresceinated DNA, and 1 µg of poly(dI–dC) as non-specific DNA. The protein solution 
containing 500 nM dimeric AcrR and 1 nM fluoresceinated DNA was titrated into the DNA-
binding solution until the millipolarization (mP) become unchanged. All measurements were 
performed at 25 °C using a PerkinElmer LS55 spectrofluorometer equipped with a 
Hamamatsu R928 photomultiplier. The excitation wavelength was 490 nm, and the 
fluorescence polarization signal (in ∆P) was measured at 520 nm. Each titration point 
recorded was an average of 15 measurements. Data were analyzed using the equation, 
P = {(Pbound – Pfree)[protein]2/(KD2 + [protein]2)} + Pfree, where P is the polarization measured 
at a given total protein concentration, Pfree is the initial polarization of free fluorescein-
labeled DNA, Pbound is the maximum polarization of specifically bound DNA, and [protein] 
is the protein concentration. The titration experiments were repeated for three times to 
obtained the average KD value. Curve fitting was accomplished using the program ORIGIN 
[31]. 
Fluorescence polarization assay for AcrR ligand-binding affinities. The experimental 
procedures for determining ligand-binding affinities of AcrR using the technique of 
fluorescence polarization were similar to that of the DNA-binding assay. The experiments 
were done using a ligand-binding solution containing 10 mM Na-phosphate (pH 7.2), 
100 mM NaCl, and 1 µM ligand (R6G, Et, or Pf). The AcrR protein solution in 10 mM Na-
phosphate (pH 7.2), 100 mM NaCl, and 1 µM ligand was titrated into the ligand-binding 
solution until the polarization (P) become unchanged. The excitation wavelengths were 527, 
483, and 447 nm, respectively, for R6G, Et, and Pf. Fluorescence polarization signals (in ∆P) 
were measured at emission wavelengths of 550, 620, and 508 nm, respectively, for these 
ligands. Each titration point recorded was an average of 15 measurements. The titration 
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experiments were repeated for three times to obtain the average KD values. Curve fitting was 
accomplished using the program ORIGIN [31]. 
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Figures and Captions 
 
Fig. 1. AcrR binding to the 28-mer cognate oligodeoxynucleotide. (A) Binding isotherm of 
AcrR in the presence of 10 mM Na-phosphate (pH 7.2), 100 mM NaCl, 1 nM fluoresceinated 
DNA, and 1 µg of poly(dI–dC) as non-specific DNA. The sequence of one of the IR strands 
is 5′-TTTACATACATTTGTGAATGTATGTACC-3′. The binding curve suggests a KD of 
20.2 ± 1.4 nM. (B) Hill plot of the data obtained for IR binding to AcrR. α corresponds to the 
fraction of bound IR. The plot gives a slope of 2.06 ± 0.12, indicating a cooperative binding 
process with a stoichoimetry of two AcrR dimers per one IR. The interception of the plot 
provides a KD of 19.2 ± 1.0 nM for the IR binding. (C) Determination of the stoichiometry of 
AcrR–DNA binding. The inflection point at an AcrR dimer concentration of 1000 nM in the 
presence of 500 nM DNA, indicating the stoichiometry of 2:1 protein-to-DNA ratio.  
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Fig. 2. Representative fluorescence polarization of AcrR with Et. (A) Binding isotherm of 
AcrR with Et, showing a KD of 4.2 ± 0.3 µM. (B) Hill plot of the data obtained for Et binding 
to AcrR. α corresponds to the fraction of bound Et. The plot gives a slope of 1.02 ± 0.02, 
indicating a simple binding process with a stoichoimetry of one AcrR protomer per one drug 
molecule. The interception of the plot provides a KD of 4.4 ± 1.0 µM. (C) Linearization of the 
data obtained for Et binding to AcrR in a Scatchard plot, indicating a KD of 4.6 ± 0.3 µM. 
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Fig. 3. Fluorescence polarization of AcrR with Pf and R6G. (A) Binding isotherm of AcrR 
with Pf, showing a KD of 10.1 ± 0.8 µM. (B) Hill plot of the data obtained for Pf binding to 
AcrR. α corresponds to the fraction of bound Pf. The plot gives a slope of 1.12 ± 0.05, and 
the interception provides a KD of 9.6 ± 1.1 µM. (C) Binding isotherm of AcrR with R6G, 
showing a KD of 10.7 ± 1.4 µM. (D) Hill plot of the data obtained for R6G binding to AcrR. 
α corresponds to the fraction of bound R6G. The plot gives a slope of 1.14 ± 0.09, and the 
interception provides a KD of 11.1 ± 1.2 µM.  
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Fig. 4. Binding of ligands by AcrR in the presence of 100 µM of Et as determined by 
fluorescence polarization assay. (A) The change in fluorescence polarization signals (∆FP) of 
Pf measured at an emission wavelength of 508 nm. The binding curve suggests a KD of 
14.9 ± 0.9 µM for Pf. (B) The change in fluorescence polarization signals (∆FP) of R6G 
measured at an emission wavelength of 550 nm. The binding curve suggests a KD of 
132.7 ± 14.6 µM for R6G. The maximum concentration of the AcrR monomer was 50 µM. 
  
60 
 
 
CHAPTER 5. Crystal Structure of the Transcriptional Regulator CmeR 
from Campylobacter jejuni 
 
A paper published in Journal of Molecular Biology 
2007, p. 583-593 Vol 372, No.3 
 
Ruoyu Gu†, Chih-Chia Su, †, Feng Shi, Ming Li, Gerry McDermott,  
Qijing Zhang and Edward W. Yu 
Abstract 
The CmeABC multidrug efflux pump, which belongs to the resistance-nodulation-division 
(RND) family, recognizes and extrudes a broad range of antimicrobial agents and is essential 
for Campylobacter jejuni colonization of the animal intestinal tract by mediating the efflux of 
bile acids. The expression of CmeABC is controlled by the transcriptional regulator CmeR, 
whose open reading frame is located immediately upstream of the cmeABC operon. To 
understand the structural basis of CmeR regulation, we have determined the crystal structure of 
CmeR to 2.2 Å resolution, revealing a dimeric two-domain molecule with an entirely helical 
architecture similar to members of the TetR family of transcriptional regulators. Unlike the rest 
of the TetR regulators, CmeR has a large center-to-center distance (54 Å) between two N 
termini of the dimer, and a large flexible ligand-binding pocket in the C-terminal domain. Each 
monomer forms a 20 Å long tunnel-like cavity in the ligand-binding domain of CmeR and is 
occupied by a fortuitous ligand that is identified as glycerol. The binding of glycerol to CmeR 
induces a conformational state that is incompatible with target DNA. As glycerol has a 
chemical structure similar to that of potential ligands of CmeR, the structure obtained mimics 
the induced form of CmeR. These findings reveal novel structural features of a TetR family 
regulator, and provide new insight into the mechanisms of ligand binding and CmeR 
regulation.  
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Introduction 
Campylobacter jejuni is the leading bacterial cause of food-borne diarrhea in the USA and 
other developed countries.1 It is also a significant enteric pathogen for young children in 
developing countries. This Gram-negative enteric organism colonizes the intestinal tracts of 
animals and has become increasingly resistant to antimicrobials due to the possession of 
multidrug efflux transporters and acquisition of various resistance mechanisms, compromising 
the effectiveness of antibiotic treatment. According to the genomic sequence of NCTC 11168, 
C. jejuni harbors 13 putative antibiotic efflux transporters of the ATP-binding cassette (ABC), 
resistance-nodulation-division (RND), multidrug and toxic compound extrusion (MATE), 
major facilitator (MF), and small multidrug resistance (SMR) families.2,3 At present, CmeABC 
and CmeDEF, which belong to the RND family, are the only two antibiotic efflux transporters 
that have been functionally characterized in Campylobacter.[4.], [5.] and [6.] 
The CmeABC efflux system is the main efflux pump in C. jejuni and consists of three 
members, including an outer membrane channel (CmeC), an inner membrane drug 
transporter (CmeB), and a periplasmic membrane fusion protein (CmeA). These three 
proteins are encoded by a three-gene operon (cmeABC) and form an efflux system that 
extrudes a variety of toxic compounds directly out of C. jejuni.5 The substrates extruded by 
CmeABC include commonly used antibiotics (e.g. fluoroquinolones, macrolides, ampicilin, 
tetracycline, chloramphenicol, cefotaxime, rifampin), metal ions (e.g. Co2+ and Cu2+), and 
lipophilic compounds (e.g. SDS and various bile salts). Thus, CmeABC contributes 
significantly to the intrinsic and acquired resistance of Campylobacter to structurally diverse 
antimicrobials.[5.], [6.], [7.] and [8.] In addition, this efflux system is essential for Campylobacter 
colonization in the animal intestinal tract by conferring resistance to the bile acids that are 
normally present in the animal intestinal tract and have bactericidal effect.9 
The expression of cmeABC is controlled by the transcriptional regulator CmeR.10 The 
cmeR gene is located immediately upstream of the cmeABC operon and encodes a 210 amino 
acid residue protein that shares N-terminal sequence and structural similarities with members 
of the TetR family of transcriptional repressors.11,12 Like other members of the TetR family, 
the N-terminal domain of CmeR contains a predicted DNA-binding helix-turn-helix (HTH) 
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motif, while its C-terminal region has unique sequences and is expected to be involved in the 
binding of inducing ligands.10,11 cmeR is transcribed in the same direction as cmeABC, and 
the intergenic region between cmeR and cmeA contains the 16 bp inverted repeat (IR) 
operator site for cmeABC. As a transcriptional regulator, CmeR binds directly to the IR 
operator and represses the transcription of cmeABC.10 This regulating process is similar to 
those of the other TetR family members, such as AcrR of Escherichia coli,13 MexR of 
Pseudomonas aeruginosa,14 MtrR of Neisseria gonorrhoeae,15 and QacR of Staphylococcus 
aureus,
16
 in which they bind specifically to the promoter sequences of acrAB, mexAB, 
mtrCDE, and qacA, respectively, thus inhibiting the expression of the corresponding efflux 
pump(s). Deletion of cmeR or mutations in the IR operator releases the repression, resulting 
in the over-expression of CmeABC, which, in turn, leads to the enhanced resistance to 
multiple antibiotics.10 
In addition, bile compounds, including both conjugated (e.g. taurodeoxycholate) and 
non-conjugated (e.g. cholate), induce the expression of cmeABC by inhibiting the binding of 
CmeR to the promoter of cmeABC, suggesting that bile compounds are inducing ligands of 
CmeR.17 It is possible that CmeR can be induced by other unidentified ligands. How 
inducing ligands bind to CmeR and modulate the expression of CmeR-controlled genes is not 
known. On the basis of the predicted structural features, we hypothesize that binding of 
inducing ligands to the C-terminal domain of CmeR triggers conformational change in the N-
terminal DNA-binding region. This change in conformation results in the release of CmeR 
from its operator DNA, and thus allows transcription from its cognate promoter. As an initial 
step to examine this hypothesis and elucidate the mechanisms that CmeR uses to regulate 
gene expression, we present here the crystal structure at 2.2 Å resolution of the CmeR 
regulator. 
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Results 
Overall structure of CmeR 
We used the multiple-wavelength anomalous dispersion method to solve the 
selenomethionyl-substituted (SeMet) CmeR crystal structure from C. jejuni. Its native crystal 
structure was then determined to 2.2 Å resolution (Table 1 and Figure 1(a)), revealing that 
only one CmeR molecule exists in the asymmetric unit. The dimeric arrangement of the 
protein was found by applying the crystallographic symmetry operators. 
The dimeric structure of CmeR, indicating an all-helical protein, is shown in Figure 
1(b). As a member of the TetR family of transcriptional regulators, CmeR consists of two 
functional motifs; an N-terminal DNA-binding domain and a C-terminal ligand-binding 
domain.[11.] and [12.] 
The crystal structure revealed that each subunit of CmeR is composed of ten α helices 
(α1–α10 and α1′–α10′, respectively) and indeed can be divided into two domains. The 
smaller N-terminal domain shares considerably high levels of sequence and structural 
similarities with the other TetR family members. For example, residues 12–65 possess 23% 
amino acid identity with and 43% similarity to that of TetR.18 This N-terminal region also 
shows 50% identity with and 71% homology to that of the QacR repressor.19 Among the 
TetR family, including TetR,[18.] and [20.] QacR,[19.] and [21.] CprB,22 and EthR,[23.] and [24.] the N-
terminal domains of these transcriptional regulators are formed by three α-helix bundles. The 
structure of CmeR, however, revealed that the third short α-helix, presumably formed by 
residues 47–53 is missing. Instead, these residues form a random coil with noticeably high B-
factors, suggesting a mobile nature of this coil. To facilitate the comparison with the 
structures of other TetR members, helices of CmeR are numbered from the N terminus as α1 
(7-29), α2 (36-43), α4 (57-81), α5 (88-104), α6 (106-118), α7 (a(125-136) and b(138-148)), 
α8 (152-170), α9 (172-180), and α10 (187-203), in which helix α3 has been skipped. In this 
arrangement, the larger C-terminal domain comprises seven α helices (α4–α10) and is 
involved in the dimerization of the repressor. According to the ligand-bound structures of 
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TetR,18 QacR,19 and EthR,24 the C-terminal region also forms the drug-binding domain. Like 
TetR, QacR and EthR, the crystal structure of CmeR suggests that helices 4–9 form the 
ligand-binding domain of the regulator. 
N-terminal domain 
The overall structure of the N-terminal DNA-binding domain of CmeR is quite 
similar to those of the TetR family members. A superposition of Cα atoms, between residues 
14 and 44, of CmeR with their corresponding residues in QacR gives an overall rmsd of 
0.8 Å. The significant sequence conservation of CmeR and QacR spans the entire N-terminal 
region and extends into the N-terminal end of helix α4. Despite these structural and sequence 
similarities, the structure of the DNA-binding domain of CmeR presents some noticeable 
differences from the rest of the TetR family members. One difference comes from helix α1. 
This first helix consists of 23 residues, which is relatively long compared with all structurally 
known members of the TetR family. For example, helices α1 in QacR,19 TetR,18 and EthR23 
are composed of 16, 13, and 17 residues, respectively. 
Perhaps, the most striking difference between structures of CmeR and other TetR 
members in the DNA-binding domain is the lack of the third N-terminal helix in CmeR. Until 
now, all known TetR family of regulators possess a helix-turn-helix (HTH) DNA- binding 
motif, which is formed by helices α2 and α3. Helix α3 is named the “recognition helix,” as it 
has a key role in binding the target DNA.12 In the case of CmeR, however, only two N-
terminal helices, α1 and α2, are found. According to the sequence alignment, residues 47–53 
are supposed to form the recognition helix α3. The crystal structure, however, shows that this 
region forms a random coil. We predicted the secondary structure of CmeR using the 
programs GOR V‡25 and PROF§.26 Both predictions describe the overall crystal structure of 
CmeR quite accurately, and they both exclude the presence of α3. 
One of the unique features of the CmeR structure is its large center-to-center distance 
between two N termini of the dimer. As CmeR does not have helix α3, we measured this 
center-to-center distance according to the separation between Cα atoms of Tyr51 and Tyr51′, 
65 
 
 
which was measured 54 Å. The corresponding distances are 39 Å and 35 Å in the apo forms 
of QacR,19 and TetR.27 These center-to-center distances increase upon ligand binding. For the 
ligand-bound dimers of QacR,19 TetR18 EthR,24 and YfiR,28 these distances become 41 Å, 
38 Å, 52 Å and 54 Å, respectively. Thus, the relatively large center-to-center distance 
observed with CmeR suggested that CmeR was liganded. 
C-terminal domain 
The C-terminal domain of CmeR consists of eight helices (α4–α10). Except helices 6 
and 9, these helices form an anti-parallel, five-helix bundle. In view of the crystal structure, 
helices 6, 8, 9 and 10 are involved in the formation of the dimer. Dimerization occurs mainly 
by couplings between pairs of helices (α6 and α9′, α8 and α10′, and their identical counter 
pairs). A surface area of 1950 Å2 per monomer (probe radius of 1.4 Å) is buried in the 
contact region of the dimer. The interaction surface is mostly hydrophobic in character. 
Within 3.5 Å, the close contact pairs in the helices involve I130 and I180′, K160 and H193′, 
I114 and Y120′, Y153 and I205′, L161 and F196′, Y116 and Y116′, and T167 and P172′. 
Additional contact interfaces are provided by the loop connecting helices 6 and 7, and the 
loop region right after helix 10. At the flexible loop between helices α6 and α7, Y120 makes 
contact with I114′ in helix α6′, while residue I205 close to the end of the C-terminus forms 
hydrophobic contacts with M154′ and L202′ from the other subunit. The dimer interface is 
further strengthened by two cross-interface hydrogen bonds formed between backbone atoms 
(between L202 and I205′, and between K113 and V119′), and a water-mediated hydrogen 
bond (between Y120 and A110′). The overall structure of the C-terminal domain of CmeR is 
closest to that of QacR among the TetR family members. Superposition of the C-terminal 
domains of CmeR and QacR suggests that helices 4–6, 7a-b, 8, and 10 of CmeR correspond 
to helices 4–6, 7, 8, and 9, respectively, of QacR. In QacR, helix α8 transits directly to the 
last helix through a nearly 180° turn.19 Similar anti-parallel arrangements of the last two C-
terminal helices are found in other TetR family members, such as EthR,23 YfiR,28 and 
CprB,22 and these last two helices are contribute mainly to dimerization. The C-terminal 
domain of CmeR is distinct, in that helix, α9, which is between the two anti-parallel helices 
α8 and α10, deviates from the direction of α8 by 40°. Thus, helix α9 bends toward the next 
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subunit of the dimer, interacting with α6′ and α7′a to secure interaction between the dimer. 
The C-terminal domain of CmeR forms a large tunnel-like cavity (Figure 2). This tunnel, 
formed predominantly by helices 4–9, opens horizontally from the front to the back of each 
protomer. The length of this tunnel is about 20 Å. Helices α7 and α8 from one subunit, and 
α9′ from the other subunit of the regulator make the entrance of the tunnel. Residues I130, 
Q134, F137 and Y139 of α7b; E159, V163 and T167 of α8; and P172′, Y173′, L176′ and 
I180′ of α9′ are involved in the formation of this entrance. 
Surrounding the inner wall of this tunnel are I68, C69, F99, F103, A108, F137 and 
S138, in which many of these residues are hydrophobic in nature. Helices 4–6, with the side-
chains of I68, H72, I102, E107 and F111, contribute to form the end of this hydrophobic 
tunnel. Similar hydrophobic tunnels have been found in the EthR[23.] and [24.] and YfiR28 
repressors. In the case of EthR, the tunnel opens vertically to the bottom of the molecule.23,24 
For YfiR, however, the long tunnel opens on one end at the subunit interface, and this end of 
the tunnel is nearly blocked by the second subunit.28 
CmeR was liganded 
The initial solvent-flattened multiple-wavelength anomalous dispersion map showed 
a positive density, presumably from an unidentified ligand that was purified and crystallized 
with the protein, inside the hydrophobic tunnel of CmeR. We used the program “putative 
active sites with spheres” (PASS)29 to search for potential ligand-binding sites in the CmeR 
structure, in which the top two predicted binding sites were located inside the hydrophobic 
tunnel. One of these two predicted sites overlaps with the unidentified positive electron 
density. The simulated annealing omit map shows that the ligand density appears to come 
from a small molecule. 
Gas chromatography coupled with mass spectrometry (GC-MS) suggests that the 
bound ligand is glycerol (1,2,3-propanetriol), as it was detected as the major component 
present in the extraction solvent (see Supplementary Data Figure S1). We used solutions 
containing glycerol to purify and crystallize the protein and it was not surprising that the 
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identified ligand is glycerol, although the finding was unexpected. The chemical structure of 
glycerol is compatible with the positive density in the simulated annealing omit map, and it 
fits unambiguously into the CmeR structure (Figure 3). 
Glycerol has not been proved to be a ligand of CmeR or an inducer of the cmeABC 
operon, the structure obtained probably mimics the ligand-bound form of CmeR. For the 
glycerol binding, the hydroxyl atom O3 forms hydrogen bonds with S138 and the backbone 
N atom of Y139 at distances of 3.1 Å and 2.7 Å, respectively. The repressor protein further 
anchors the bound glycerol through two water-mediated hydrogen bonds, between T167 and 
hydroxyl atom O2 (through OW1) and between S138 and hydroxyl atom O1 (through OW2) 
of the bound glycerol. The SG of C166 and NZ of K170 are less than 4 Å away from O2 and 
O1, respectively, interacting with the bound glycerol and securing the binding. 
Predicting the structure of the DNA-bound form of CmeR 
Although we expect that the DNA-binding mode of CmeR is similar to that of TetR, 
the overall crystal structure and sequence alignment suggest that the CmeR protein is more 
similar to the QacR repressor. Thus, a speculative model of DNA-bound CmeR was 
generated by the alignment of its individual domains with those of the DNA-bound QacR 
(Figure 4). This model reveals an extensive movement in CmeR that might allow a shift from 
a ligand-bound form to a DNA-bound form of the repressor, although we cannot exclude the 
fact that the target DNA itself may also undergo conformational changes allowing binding to 
CmeR as seen for TetR,20 QacR21 and BmrR.30 On the basis of this DNA-bound model, it is 
speculated that helix α6 moves toward α9 during DNA binding, resulting in a decrease in 
volume of the ligand-binding site 
Docking of ligands into the hydrophobic tunnel 
To elucidate different binding modes of CmeR to a variety of ligands, we used the 
program MEDock31 to identify potential binding pockets for two bile acids, taurocholate and 
cholate. We first predicted a glycerol-binding site in CmeR (Figure 5(a)). This predicted site 
overlaps with the glycerol-binding site identified from the crystal structure, suggesting 
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MEDock is sufficiently precise for identification of potential protein-binding pockets. When 
MEDock was used to search for a taurochloate-binding site in CmeR, it was found that the 
taurocholate molecule was bound inside the tunnel, spanning the two PASS predicted ligand-
binding sites. Taurocholate is a 19 Å long ligand, and spans almost the entire length of the 
ligand-binding tunnel (Figure 5(b)). For the predicted cholate binding in CmeR, cholate binds 
inside the tunnel, very similar to taurocholate binding (Figure 5(c)). 
Discussion 
The structural similarity of the N-terminal domains of members of the TetR family 
suggests a similar mode of interaction with target DNAs. CmeR represses the transcription of 
cmeABC by binding directly to the inverting 16 bp IR sequence in the promoter region of the 
efflux operon. This IR sequence is similar in length to that of the 15 bp tetO bound by TetR, 
but is different from the long 28 bp IR1 recognized by QacR. TetR binds as a single dimer to 
the tetO operator;20 however, two dimers of QacR interact with one IR1.21 On the basis of the 
IR sequence, we reasoned that CmeR might bind its operator as a dimer, similar to the TetR 
DNA binding. 
The separation between two successive major grooves of a 16 bp double helix should 
be less than 40 Å (the distance between two consecutive major grooves of B-DNA is 34 Å). 
The ligand-bound structure of CmeR indicates that the two DNA recognition regions of the 
dimer are separated by 54 Å, which is incompatible with the binding of the regulator to its 
16 bp operator. Thus, it is possible that a drastic change in conformation of the DNA-binding 
domain of CmeR might take place during the process of binding target DNA. This change 
should be greater compared with that of QacR and TetR. In the case of QacR, the change in 
conformation is accompanied by an increase in the center-to-center distance from 37 Å of the 
DNA-bound form to 48 Å of the ligand-bound form.22 For TetR, however, this change is less 
obvious. The center-to-center distance of the TetR dimer shifts only from 35 Å in the DNA-
bound structure to 38 Å in the ligand-bound structure.20 On the basis of the DNA-bound 
model of CmeR, it is speculated that this center-to-center distance may decrease to 36 Å 
upon DNA binding (Figure 4). This change may trigger a coupling movement of helices α6 
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and α9, resulting in a decrease in size of the ligand-binding tunnel, which in turn hinders the 
inducer ligand to enter the ligand-binding site. The consequence is that the inducer ligand has 
to overcome this steric hindrance in order to bind CmeR. Thus, it is likely that CmeR 
induction may be governed by steric repulsion that takes place during inducer binding. The 
crystal structures of both ligand-free and DNA-bound CmeR would be necessary to infer the 
mechanisms of CmeR induction, and to confirm our speculative models based on the 
glycerol-bound CmeR structure. 
The lack of the recognition helix, α3, in the DNA-binding domain of the CmeR 
structure is unique among members of the TetR family. Secondary structure prediction using 
programs GOR V25 and PROF26 also suggests that this segment (residues 47–53) is likely to 
form a random coil. An α-helix is stabilized mainly by a favorable enthalpic contribution 
from the formation of the backbone hydrogen bonds and van der Waals interactions.32,33 
However, a random coil is mostly favored by conformational entropy that degenerates 
different conformational states of the coil.34 The entropic cost of fixing the backbone dihedral 
angles in forming an α-helical structure is within 2 kcal/mol at 25 °C.33,35,36 We reasoned that 
in the case of CmeR, the energy difference between α-helical and randomly coil states of the 
recognition helix are very close, in the range of 1–2 kcal/mol. If this is the case, it is possible 
that the segment forming α3 is more favorable for formation of the flexible coil state in the 
absence of target DNA. This segment will transform into an α-helical conformation upon 
DNA binding due to the release of energy from the formation of hydrogen bonds and contact 
interactions between the repressor and target DNA. On the basis of a helix propensity scale,37 
we estimated the amount of energy involved in helix formation of the last five residues in the 
recognition segment. This estimated energy in CmeR is 3.3 kcal/mol, which is about 
1 kcal/mol greater when compared with those of TetR (2.5 kcal/mol), QacR (2.5 kcal/mol), 
EthR (2.7 kcal/mol), and CprB (1.9 kcal/mol). It seems that in CmeR this segment has less 
tendency to form α-helix. However, this extra 1 kcal/mol is not excessive and can be 
compensated easily by the release of energy during repressor–operator interaction. 
One striking feature of the CmeR structure is the large ligand-binding tunnel in each 
monomer. This tunnel, nearly 20 Å in length, is surrounded by mostly hydrophobic residues 
70 
 
 
of helices 4–9, and occupies a volume of about 1000 Å3. Each hydrophobic tunnel spans 
horizontally across the C-terminal domain, and can be seen through from the front to the 
back of the dimer without obstruction. This unique feature, in the TetR family of regulators, 
highlights the flexibility of the CmeR regulator. Unexpectedly, the crystal structure of CmeR 
revealed the presence of a glycerol molecule inside this large ligand-binding tunnel. Glycerol 
binds identically in each subunit, as indicated by the crystallographic 2-fold symmetry of the 
CmeR dimer (Figure 1(b)). This ligand-binding mode is different from that of QacR, in 
which one dimer of QacR binds one drug,19 but similar to that of TetR, which interacts with 
tetracycline in a 1:1 monomer/drug molar ratio.18 The volume of the ligand-binding tunnel of 
CmeR is large enough to accommodate a few of the ligand molecules. Additional water 
molecules fill the portion of the large tunnel that is unoccupied by ligand. When PASS29 was 
used to search for potential ligand-binding sites in the CmeR structure, the top two predicted 
sites, which are 8.4 Å apart, were found inside this hydrophobic tunnel. One of these 
predicted sites corresponds to the glycerol-binding site. The second predicted site, however, 
is still empty. Thus, CmeR might be able to accommodate a much bigger ligand that spans 
across these two predicted binding sites. There is also a good chance that CmeR, like QacR, 
could bind two drug molecules at a time.38 In any case, the flexibility of the large ligand-
binding tunnel suggests that CmeR is a multiple ligand-binding protein. 
Although the ligand-binding tunnel is mainly hydrophobic in nature, the electrostatic 
surface diagram (Figure 2(a)), somewhat surprising, displays a patch of positive surface 
potential inside the tunnel. This positive potential indicates that CmeR may be more 
favorable to bind neutral and negatively charged ligands. In fact, many of the CmeR ligands, 
such as bile acids, are negative in charge. To examine how CmeR binds a variety of ligands, 
we used MEDock to predict the binding sites of cholate and taurocholate. The docking study 
suggested that the bound cholate and taurocholate, respectively, occupied both of the PASS 
predicted sites in the hydrophobic tunnel. These binding modes are similar to that of the 
dequalinium binding in QacR, in which the bound dequalinium took both the rhodamine 6G 
and ethidium-binding sites.19 
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CmeR represses the expression of the CmeABC efflux pump that extrudes various 
bile salts, such as cholate, deoxycholate and taurocholate. It also recognizes commonly used 
antibiotics, including fluoroquinolones, macrolides, tetracycline and rifampin. Thus, these 
compounds are the CmeR ligands. It has not been shown that glycerol is a natural ligand of 
CmeR. The biological effect of CmeR binding by glycerol remains to be determined. 
Recently, it has been shown using DNA microarray that CmeR may function as a pleiotropic 
regulator modulating the expression of multiple membrane transporters, including two C4-
dicarboxylate transporters DcuA and DcuB (Q.Z., unpublished results). This finding suggests 
that C4-dicarboxylates, such as malate, fumurate, succinate and aspartate, might be ligands 
for CmeR. The chemical structures of glycerol (which is bound by CmeR) and C4-
dicarboxylates are quite similar, suggesting that CmeR may recognize and respond to C4-
dicarboxylate compounds. 
Materials and Methods 
Purification, crystallization and data collection 
Recombinant CmeR, containing a His6 tag at the N terminus, was produced in 
Escherichia coli using the pQE30 vector. The cloning, expression, purification and 
crystallization procedures have been described.5,9,10,39 Diffraction data sets of both the native 
and SeMet-CmeR crystals were taken at the Advanced Light Source (beamline 8.2.2) at 
cryogenic temperature (100 K) using an ADSC Quantum 315 CCD-based detector. 
Structural determination and refinement 
Diffraction data sets were processed with DENZO and scaled with SCALEPACK.40 
Both native and SeMet crystals took the space group group of P21212, with the unit cell 
parameters given in Table 1. Initial phase calculation was carried out at 2.8 Å resolution 
using the program BnP41 after finding and refinement of all three selenium sites. The electron 
density map obtained was applied to density modification (DM) using the program 
RESOLVE.42 The auto-interpretation routine program in RESOLVE led to an initial model 
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containing 78% amino acid residues, 50% of which contained side-chains. The remaining 
part of the model was constructed manually using the program O.43 The model, comprising 
residues 6–207, was then refined against thenative data at 2.2 Å using the programs CNS44 
and REFMAC5.[45.] and [46.] Solvent atoms were initially built using the program ARP/warp45,47 
and later added or removed by manual inspection. The final R-factor and Rfree (calculated 
with 5% of the reflections omitted from the refinement) were 21.9% and 24.3%, respectively. 
Modeling of DNA-bound form of CmeR 
The model of the DNA-bound form of CmeR was generated using O.43 In brief, the N 
and C-terminal domains of CmeR were separately aligned with the corresponding domains of 
the DNA-bound QacR (1JT021). The resulting model was then idealized using 
REFMAC5.45,46 The CmeR dimer was generated by applying symmetry operators obtained 
from the ligand-bound CmeR crystal structure. The recognition helix α3 was also placed 
accordingly. The final center-to-center distance of the DNA-bound form of CmeR is 36 Å. 
Prediction of ligand-binding sites 
The MEDock web server31 was used for prediction of the taurocholate (PDB tch) and 
cholate (PDB chd) bindings in CmeR. A global search strategy that exploits the maximum 
entropy property of the Gaussian distribution was employed. For the docking protocol, the 
maximum generation in each run was set to 1000. A grid of 0.375 Å spacing was used for the 
calculation. Five separate docking calculations were performed for each ligand,. Each 
calculation was performed with a population size of 50, and a probability of 0.05 to invoke 
local search. 
Identification of fortuitous ligand 
We used GC-MS to identify the nature of the bound ligand in crystals of CmeR. The 
CmeR crystals were washed extensively with the crystallization buffer and transferred into 
deionized water. The mixture was incubated at 100 °C for 5 min, and subsequently methanol 
was added into the mixture to a final concentration of 80% (v/v) to denature the protein and 
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allow for the extraction of ligand. The GC-MS results suggested that the bound ligand is 
glycerol (1,2,3-propanetriol) (see Supplementary Data). 
Protein Data Bank accession code 
Coordinates and structural factors for the structure of CmeR have been deposited with the 
RCSB Protein Data Bank with accession code 2QCO. 
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Figures and Captions 
  
Figure 1. Stereo view of the experimental density map and ribbon diagram of CmeR. (a) 
Representative section of electron density at the subunit interface. The solvent-flattened 
electron density (50–2.3 Å) is contoured at the 1σ level and superimposed with the final refined 
model (yellow, carbon; red, oxygen; blue nitrogen; green, sulfur). (b) Ribbon diagram of the 
ligand-bound CmeR homodimer generated by crystallographic symmetry. The Figure was 
prepared using PyMOL [http://www.pymol.sourceforge.net]. 
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Figure 2. Views of the tunnel-like cavity in the ligand-binding domain of CmeR. (a) 
Electrostatic surface potential of one subunit of CmeR. This view shows the long tunnel 
spanning through the C-terminal domain of CmeR. Blue (+15 kBT) and red (−15 kBT) indicate 
the positively and negatively charged areas of the protein, respectively, (b) View of the 
hydrophobic cavity with residues forming the tunnel. The Figure was prepared using PyMOL 
[http://www.pymol.sourceforge.net]. 
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Figure 3. Simulated annealing omit map of the glycerol binding pocket. A stereo view of the 
composed electron density omit map (contoured at the 1.5 σ level) calculated by excluding 
glycerol from the model. Carbon atoms are colored grey for bound glycerol and light orange 
for protein residues. Nitrogen, oxygen, and sulfur atoms are colored blue, red, and orange, 
respectively. The two top binding-site centers predicted from PASS are depicted as pink 
dotted-spheres. Two water molecules (OW1 and OW2) located at the glycerol-binding site are 
shown as red balls. 
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Figure 4. Speculative model of CmeR in its DNA-bound form. The N and C-terminal domains 
of the ligand-bound dimeric CmeR were individually aligned with those of the DNA-bound 
QacR (1JT0) to generate the DNA-bound form of CmeR. The two DNA recognition α3 helices 
in the dimer of CmeR are included in the model. 
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Figure 5. Binding site prediction for CmeR. (a) CmeR complexed with glycerol. The bound 
glycerol moleculess from the crystal structure and from prediction are colored pink and yellow, 
respectively. (b) CmeR complexed with taurocholate. The bound taurocholate from prediction 
is colored orange. (c) CmeR complexed with cholate. The bound cholate from prediction is 
colored yellow. All predictions were done using MEDock. The two top binding-site centers 
predicted from PASS are depicted as green dotted-spheres. 
  
83 
 
 
CHAPTER 6. Crystallization and preliminary X-ray diffraction 
analysis of the multidrug efflux transporter NorM from Neisseria 
gonorrhoeae 
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Abstract 
The crystallization and preliminary X-ray data analysis of the NorM multidrug efflux 
pump produced by Neisseria gonorrhoeae are reported. NorM is a cytoplasmic membrane 
protein that consists of 459 amino-acid residues. It is a member of the recently classified 
multidrug and toxic compound extrusion (MATE) family of transporters and recognizes a 
number of cationic toxic compounds such as ethidium bromide, acriflavin, 2-N-
methylellipticinium and ciprofloxacin. Recombinant NorM protein was expressed in 
Escherichia coli and purified by metal-affinity and gel-filtration chromatography. The protein 
was crystallized using hanging-drop vapor diffusion. X-ray diffraction data were collected 
from cryocooled crystals at a synchrotron light source. The best crystal diffracted 
anisotropically to 3.8 Å and diffraction data were complete to 6.5 Å resolution. The space 
group was determined to be C2, with unit-cell parameters a = 81.5, b = 164.4, c = 111.5 Å. 
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Introduction 
Gonorrhea is one of the most common sexually transmitted diseases in the world. It is 
estimated that 800 000 cases of gonorrhea occur annually in the USA at a cost of $1.1 billion 
(http://www.thebody.com/content/art6532.html ). The disease is caused by the Gram-
negative bacterium Neisseria gonorrhoeae, which is increasingly resistant to most 
inexpensive antibiotics, including penicillin, tetracycline, erythromycin and ciprofloxacin. In 
April 2007, the Centers for Disease Control and Prevention (CDC) officially added 
gonorrhea to the list of antibiotic-resistant `superbugs' 
(http://www.cdc.gov/std/Gonorrhea/STDFact-gonorrhea.htm ). Since N. gonorrhoeae is a 
strict human pathogen and can colonize male and female genital mucosal surfaces and other 
sites, it has developed mechanisms to overcome the host antimicrobial systems that are 
essential to innate host defense (Shafer et al., 2001). One important mechanism that N. 
gonorrhoeae uses to subvert antimicrobial agents is the expression of multidrug efflux 
transporters. These transporters recognize and actively export a wide variety of structurally 
unrelated toxic compounds, including antibacterial peptides, long-chain fatty acids and 
several clinically useful antibiotics, from the bacterial cell (Lee & Shafer, 1999; Shafer et al., 
1998, 2001; Rouquette-Loughlin et al., 2003). 
Four efflux transporters have been identified in N. gonorrhoeae. One such transporter 
is the MtrD inner membrane protein (Hagman et al., 1997), which exists as a component of 
the tripartite resistance nodulation cell division (RND) efflux pump (Tseng et al., 1999). This 
pump mediates the export of hydrophobic antimicrobial agents including antibiotics, 
nonionic detergents, certain antibacterial peptides, bile salts and gonadal steroid hormones 
from the bacterium (Shafer et al., 1998; Delahay et al., 1997; Hagman et al., 1995, 1997). 
The FarB transporter (Lee & Shafer, 1999), which belongs to the major facilitator (MF) 
family (Griffith et al., 1992; Marger & Saier, 1993; Pao et al., 1998), recognizes antibacterial 
long-chain fatty acids and exports them out of the cell. MacB has recently been described 
(Rouquette-Loughlin et al., 2005) and belongs to the ATP-binding cassette (ABC) 
transporter family (Higgins, 1992). It is poorly expressed in wild-type gonococci owing to a 
natural mutation in its promoter, but can recognize and export certain macrolide antibiotics. 
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Finally, N. gonorrhoeae contains the NorM multidrug transporter (Rouquette-Loughlin et al., 
2003), which is a member of the most recently classified multidrug and toxic compound 
extrusion (MATE) family of efflux pumps (Rouquette-Loughlin et al., 2003; Brown et al., 
1999; Morita et al., 1998). As a multidrug efflux pump, the gonococcal NorM appears to 
recognize a number of cationic toxic compounds such as ethidium bromide, acriflavin, 2-N-
methylellipticinium and ciprofloxacin (Rouquette-Loughlin et al., 2003). We recently 
determined that NorM binds a variety of structurally dissimilar agents in the micromolar 
range and behaves as an Na+-dependent transporter (Long et al., 2008). The capacity of 
NorM to export the antibiotic ciprofloxacin is recognized as being clinically relevant in the 
development of fluoroquinolone resistance in N. gonorrhoeae. 
The MATE transporters characteristically possess 12 putative transmembrane 
domains. To date, the overall properties of the MATE family of proteins have not been 
completely determined and no structural models are available for this type of multidrug 
resistance-conferring protein. As an initial step to elucidate the structural basis of multidrug 
recognition and extrusion by NorM, we here report the crystallization and preliminary X-ray 
diffraction analysis of the NorM transporter. 
Cloning, expression and purification 
2.1. Cloning 
Recombinant full-length NorM containing a 6×His tag directly attached to the C-
terminal end (C-6×His) was produced in Escherichia coli TOP10 cells using the pBAD 
vector (Invitrogen). The cloning and expression procedures have been described previously 
(Long et al., 2008). This recombinant C-6×His NorM is fully functional in vivo and the 
purified protein has been demonstrated to bind antimicrobials in a detergent environment 
with dissociation constants spanning the micromolar range (Long et al., 2008). 
To produce recombinant full-length NorM containing a 6×His tag at the N-terminus, 
the ORF for norM from the genomic DNA of N. gonorrhoeae strain FA19 was amplified by 
PCR using the primers 5'-AAACATATGCTGCTCGACCTCGACCGC-3' and 5'-
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AAAGGATCCTCAGACGGCCTTGTGTGATTTGC-3'. The 1380 bp PCR fragment of the 
norM gene with flanking sequences was extracted from the agarose gel using a gel-extraction 
kit (Qiagen) and then digested with NdeI and BamHI (New England Biolabs). The digested 
products were ligated into the pET15b expression vector (Novagen) to generate a 
recombinant protein that contains a 6×His tag, a thrombin-cleavage site and a three-residue 
(GSH) N-terminal spacer attached to the N-terminal end of NorM (N-6×His). The sequence 
of this N-6×His NorM protein is MGSSHHHHHHSSGLVPRGSH-NorM. This recombinant 
plasmid (pET15b norM) was transformed into DH5  cells and selected on LB plates 
containing 100 µg ml-1 ampicillin. The construction was verified by DNA sequencing. 
2.2. Protein expression 
The C-6×His NorM protein was overproduced in E. coli TOP10/pBAD norM cells 
as described elsewhere (Long et al., 2008). As these cells cannot be grown in M9 minimal 
media, recombinant selenomethionyl-NorM (SeMet-NorM) protein was overproduced using 
the N-6×His construct in E. coli B834/pET15 norM cells. Briefly, a 10 ml overnight culture 
in Luria-Bertani (LB) broth was transferred into 120 ml LB broth containing 100 µg ml-1 
ampicillin. The culture was grown with shaking (210 rev min-1) at 310 K. When the OD600 
value reached 1.2, cells were harvested by centrifugation at 6000 rev min-1 for 10 min and 
then washed two times with 20 ml M9 minimal salts solution. The cells were resuspended in 
120 ml M9 media and then transferred into 12 l pre-warmed M9 solution containing 
100 µg ml-1 ampicillin. The cell culture was incubated at 310 K with shaking. When the 
OD600 reached 0.4, 60 mg l-1 L-selenomethionine was added. The culture was then induced 
with 1 mM isopropyl -D-1-thiogalactopyranoside (IPTG) after 15 min. Cells were 
harvested within 3 h and were frozen and stored at 193 K. 
2.3. Protein purification 
The C-6×His NorM protein was purified using an Ni2+-affinity column as described 
in Long et al. (2008), followed by a G-200 sizing column to enhance purity. This step was 
also essential to exchange n-dodecyl- -D-maltoside ( -DDM) with different detergents for 
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crystallization attempts. The procedure for detergent exchange using gel-filtration 
chromatography was as follows: the purified C-6×His NorM protein in buffer containing 
20 mM Na HEPES pH 7.5 and 0.1% -DDM was concentrated to a volume of 800 µl (
10 mg ml-1) using a YM-100 concentrator (Millipore, 100 kDa molecular-weight cutoff). The 
concentrated protein was then loaded onto a Superdex 200 (G-200) 16/60 column 
(Amersham Pharmacia Biotech) pre-equilibrated with buffer containing 20 mM Na HEPES 
pH 7.5 and the relevant detergent at the described concentration. The volume and length of 
the G-200 sizing column were 120 ml and 60 cm, respectively. A flow rate of 0.5 ml min-1 
was used and 2 ml fractions were collected and analyzed by 10% SDS-PAGE. 
The purification procedures for the N-6×His SeMet-NorM protein were similar to 
those used for C-6×His NorM. In brief, the N-6×His SeMet protein was purified using an 
Ni2+-affinity column as described in Long et al. (2008). The purified protein was extensively 
dialyzed against buffer containing 20 mM Na HEPES pH 7.5 and 0.1% -DDM, 
concentrated to 2 mg ml-1 and then incubated for 24 h at 298 K in the presence of one unit of 
thrombin per 2 mg protein to cleave the hexahistidine tag. After thrombin cleavage, the 
newly formed SeMet-NorM protein, which contained a three-residue spacer, GSH, directly 
attached to the N-terminus (GSH-SeMet-NorM), was loaded onto a G-200 sizing column 
pre-equilibrated with buffer containing 20 mM Na HEPES pH 7.5 and 0.1% -DDM for 
further purification. The purity of the purified GSH-SeMet-NorM protein was judged using 
10% SDS-PAGE stained with Coomassie Brilliant Blue. NorM is a 459-amino-acid protein 
that contains 19 methionines. Replacement of these methionine sulfurs with seleniums in the 
GSH-SeMet-NorM protein was confirmed by MALDI time-of-flight mass spectrometry. 
Both the C-6×His NorM and GSH-SeMet-NorM proteins were concentrated to 
20 mg ml-1 in solution containing 20 mM Na HEPES pH 7.5 and 0.1% -DDM. Typical 
starting and ending volumes were 10 ml and 300 µl, respectively. To avoid concentrating -
DDM in the protein solution, a YM-100 Centriprep concentrator (Millipore, 100 kDa 
molecular-weight cutoff) was used for protein concentration. The 100 kDa molecular-weight 
cutoff concentrators have been shown to be efficient enough to avoid concentrating the -
DDM micelles (Urbani & Warne, 2005). 
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3. Crystallization 
3.1. Detergents 
The full-length C-6×His NorM protein containing six histidines at the C-terminus was 
crystallized in 24-well plates using the hanging-drop vapor-diffusion method. Initial 
crystallization trials using commercially available screening kits, including Hampton Crystal 
Screens I, II and Lite, PEG/Ion and MembFac, failed. Accordingly, we performed 
crystallization screening by mixing different polyethylene glycols [PEGs; ranging from PEG 
200 to PEG 20 000 and PEG 550 MME (monomethyl ether) to PEG 5500 MME] with 
different buffers (between pH 3.5 and pH 9.5), salts, additives and detergents. The 
experiments were performed at 277 or 298 K. 
Initially, five different detergents, -DDM, n-dodecyl- -D-maltoside ( -DDM), 
polyoxyethylene(8)dodecyl ether (C12E8), n-undecyl- -D-maltoside (UDM), n-tetradecyl- -
D-maltoside (TDM) and n-octyl- -D-glucoside (OG), were used as primary detergents in 
our crystallization trials. The experiments suggested that protein solution containing 0.1% -
DDM or 0.8% OG resulted in the formation of protein crystals. Crystals grown in the 
presence of -DDM diffracted to 8 Å; however, those grown in the presence of OG did not 
diffract X-rays. Thus, -DDM was chosen as the primary detergent for further crystallization 
trials. 
We attempted to improve the quality of the crystals by searching for a suitable 
secondary detergent using Detergent Screens 1, 2 and 3 (Hampton Research). After the initial 
screen, eight different secondary detergents, C12E8, UDM, polyoxyethylene(9)dodecyl ether 
(C12E9), 6-cyclohexyl-1-hexyl- -D-maltoside (Cymal-6), n-decyl- -D-maltoside (DM), n-
dodecylphosphocholine (Fos-choline-12), n-nonyl- -D-glucoside (NG) and 3-(3-butyl-3-
phenylheptanamido)-N,N-dimethylpropan-1-amine oxide (TRIPAO), were chosen for further 
trials. However, it appeared that the addition of these secondary detergents did not improve 
the diffraction limit of the crystals. 
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3.2. Removal of hexahistidine tags 
We then created a thrombin-cleavage site at position 454 of the protein in order to 
remove the hexahistidine tag at the C-terminus of C-6×His NorM. After removing the 6×His 
tag, this NorM protein (NorM454, amino acids 1-454) was purified in -DDM and subjected 
to a broad screen with various PEGs, salts, buffers, additives and detergents as described 
above. Unfortunately, crystals of the NorM454 protein diffracted X-rays in a similar manner 
to those of C-6×His NorM and did not appear to enhance the resolution limit. 
We also attempted to improve the crystal quality by crystallizing N-6×His NorM. 
After the removal of the 6×His tag using thrombin, this NorM protein, GSH-NorM, 
containing a three-residue spacer (GSH) at the N-terminal end, was screened with various 
PEGs, salts, buffers, additives and detergents as above. However, the best crystal obtained 
was no better than that obtained for C-6×His NorM. We thus focused our subsequent 
crystallization efforts on the C-6×His NorM protein. 
3.3. Crystallization conditions 
For hanging-drop vapor diffusion, a 2 µl drop consisting of 1 µl protein solution 
(20 mg ml-1 NorM in 20 mM Na HEPES pH 7.5 and 0.1% -DDM) and 1 µl reservoir 
solution was equilibrated against 500 µl reservoir solution. The initial crystals of NorM were 
grown in 15-18% PEG 1000 and 20-100 mM Na HEPES pH 7.5. After optimization, the best 
C-6×His NorM crystals were obtained at 298 K from well solution containing 16% PEG 
1000, 40 mM Na HEPES buffer pH 7.5 and 4% glycerol. Crystals appeared within one week 
and typically had dimensions of about 200 × 200 × 200 µm. Fig. 1 illustrates a typical native 
crystal of C-6×His NorM. Cryoprotection was achieved by raising the PEG 1000 
concentration stepwise to 26% in 5% increments. Crystals of the GSH-SeMet-NorM protein 
(after removal of the 6×His tag at the N-terminus) were grown under the same conditions. 
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4. Data collection and processing 
For data collection, a single native crystal of C-6×His NorM was flash-cooled in a 
cryoprotectant solution containing 26% PEG 1000, 40 mM Na HEPES buffer pH 7.5 and 4% 
glycerol at 100 K. The best crystal diffracted anisotropically to a resolution of 3.8 Å. Fig. 2 
depicts one of the diffraction images of the native NorM crystal. Single-wavelength 
anomalous diffraction data were collected at the peak wavelength from a single GSH-SeMet-
NorM crystal. The best native C-6×His NorM and GSH-SeMet-NorM diffraction data were 
obtained to resolutions of 6.5 and 7.2 Å, respectively (Table 1) 
Diffraction data sets were obtained from the native C-6×His NorM crystals at the 
Advanced Photon Source (APS, beamline 24IDC) at cryogenic temperature (100 K) using an 
ADSC Quantum 315 CCD-based detector. The beam size was 50 × 20 µm. Data for the 
GSH-SeMet-NorM crystals were obtained at the Advanced Light Source (ALS, beamline 
8.2.2) at cryogenic temperature (100 K) using an ADSC Quantum 315 CCD-based detector. 
The beam size was 140 × 150 µm. Diffraction data sets were processed with DENZO and 
scaled with SCALEPACK (Otwinowski & Minor, 1997). The native C-6×His NorM crystal 
belonged to space group C2, with unit-cell parameters a = 81.5, b = 164.4, c = 111.5 Å. The 
GSH-SeMet-NorM crystal belonged to the same space group with very similar unit-cell 
parameters (Table 1). Based on the molecular weight of the C-6×His NorM protein 
(50.6 kDa, including the 6×His tag at the C-terminus) and the volume of the asymmetric unit, 
the Matthews parameters (Matthews, 1968, 1977) for one and two molecules of NorM in the 
asymmetric unit were found to be 7.0 and 3.5 Å3 Da-1, respectively. This suggests the 
presence of one or two NorM molecules per asymmetric unit, with solvent contents of 82.2% 
or 64.4%, respectively. 
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Figures and Captions 
 
 
Figure 1  
N. gonorrhoeae C-6×His NorM crystal. The dimensions of the crystal are approximately 200 
× 200 × 200 µm. 
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Figure 2  
X-ray diffraction pattern of the native C-6×His NorM crystal. The crystal diffracted 
anisotropically to a resolution beyond 3.8 Å. 
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Table1 
Data collection and crystallographic analysis of NorM 
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Abstract 
Gram-negative bacteria, such as Escherichia coli, frequently utilize tripartite efflux 
complexes belonging to the resistance-nodulation-division family to expel diverse toxic 
compounds from the cell.  These systems contain a periplasmic membrane fusion protein that 
is critical for substrate transport.  We here present the x-ray structures of the CusB membrane 
fusion protein from the copper/silver efflux system of E. coli.  This is the first structure of any 
membrane fusion proteins associated with heavy-metal efflux transporters.  CusB bridges the 
inner membrane efflux pump CusA and outer membrane channel CusC to mediate resistance to 
Cu+ and Ag+ ions.  Two distinct structures of the elongated molecules of CusB were found in 
the asymmetric unit of a single crystal, which suggests the flexible nature of this protein.  Each 
protomer of CusB can be divided into four different domains, whereby the first three domains 
are mostly β-strands and the last domain adopts an entirely helical architecture.  Unlike other 
known structures of membrane fusion proteins, the α-helical domain of CusB is folded into a 
three-helix bundle.  This three-helix bundle presumably interacts with the periplasmic domain 
of CusC.  The N and C-termini of CusB form the first β-strand domain, which is thought to 
interact with the periplasmic domain of the CusA efflux pump.  These findings reveal novel 
structural features of a membrane fusion protein in the resistance-nodulation-division efflux 
system, and provide new insight into the mechanisms of heavy-metal extrusion by CusB. 
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Introduction 
Silver is a heavy metal with relatively high toxicity to prokaryotes.  Ionic silver exhibits 
antimicrobial activity against a broad range of microorganisms, and is used widely as an 
effective antimicrobial agent to combat pathogens.1,2  Copper, although required in trace 
amounts for bacterial growth, is highly toxic even at low concentrations.3  Thus, both silver and 
copper are well-known bactericides, and their biocidal effects have been used for centuries.  It 
has been shown that silver and copper ions effectively eliminate Legionella in drinking water 
pipelines.4  Silver and copper ions are capable of penetrating biofilms that build up in hospital 
plumbing, destroying entrenched Legionella and other pathogenic organisms.4,5  In addition, 
silver cations are commonly employed in treating patients with burns, wounds, eye infections 
and ulcers.1  To date, the antimicrobial uses of ionic copper have been expanded to include 
fungicides, antifouling paints, antimicrobial medicines and antiseptics.6  Because of the 
widespread use of silver and copper as antimicrobial agents, the presence of silver and copper 
resistant bacterial strains appear to be on the rise.1,2,7-9   
Bacteria, such as Escherichia coli, have developed various mechanisms to overcome 
toxic environments that are unfavorable to their survival.  One important strategy that bacteria 
use to subvert toxic compounds, including toxic metal ions such as Ag+ and Cu+, is the 
expression of membrane efflux transporters that recognize and actively export these 
compounds out of bacterial cells, thereby allowing them to survive in extremely toxic 
conditions.  In Gram-negative bacteria, efflux systems of the resistance-nodulation-division 
(RND) family play major roles in the intrinsic and acquired tolerance of antibiotics and toxic 
compounds.10,11  As a Gram-negative bacterium, E. coli contains seven different RND efflux 
transporters.  Six of these transporters, including AcrB, AcrD, AcrF, MdtB, MdtC and YhiV, 
are multidrug efflux pumps.  They belong to the hydrophobic and amphiphilic efflux RND 
(HAE-RND) protein family.10  E. coli consists of only one heavy-metal efflux RND (HME-
RND) transporter, CusA, which specifically recognizes and confers resistance to Ag(I) and 
Cu(I) ions.12,13 
Typically, an RND transporter works in conjunction with a periplasmic component, 
belonging to the membrane fusion protein (MFP) family,14,15 and an outer membrane channel 
to form a functional protein complex.16  The resulting tripartite efflux system spans the inner 
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and outer membranes of Gram-negative bacterium to export substrates directly out of the cell.16  
For the CusA inner membrane transporter, it interacts with the periplasmic membrane fusion 
protein CusB and the outer membrane channel CusC to form the CusABC tripartite efflux 
complex.12,13  Heavy-metal efflux by CusABC is driven by proton import.  This process is 
catalyzed through the inner membrane transporter CusA.      
Among all known RND family of transporters, the E. coli AcrB17-20 and Pseudomonas 
aeruginosa MexB21 HAE-RND pumps are the only two membrane proteins that have been 
crystallized.  These proteins span the entire width of the inner membrane and protrude 
approximately 70-Å into the periplasm.  The crystal structures of the outer membrane channels, 
E. coli TolC and P. aeruginosa OprM, have also been determined.22,23  TolC is anchored in the 
outer membrane and forms a 100-Å-long periplasmic α-helical tunnel.22  The P. aeruginosa 
OprM channel possesses a similar elongated α-helical tunnel that projects into the periplasmic 
space.23  Recently, two structures of the periplasmic membrane fusion proteins, E. coli AcrA24 
and P. aeruginosa MexA,25-27 associated with the HAE-RND transporters have been solved.  
The structures suggest that these two periplasmic proteins are folded into elongated secondary 
structures that consist of ~47-Å-long α-hairpin domain, presumably interacting with the α-
helical tunnels of their corresponding outer membrane channels.  Further, the N and C-terminal 
ends of these membrane fusion proteins are thought to contact their respective inner membrane 
transporters, creating a functional complex that spans both membranes.        
Currently, no structural information is available for any components of the HME-RND 
tripartite efflux complex.  Presumably, the three components of the HME-RND system form a 
tripartite complex that resembles the AcrAB-TolC complex.  Different from the HAE-RND 
family, members of the HME-RND family are highly substrate specific, with the ability to 
differentiate between monovalent and divalent ions.  As an initial step to examine the 
mechanisms used by the CusABC efflux system to facilitate Ag(I) and Cu(I) ions recognition 
and extrusion, we here describe the crystal structure, at 3.4 Å resolution, of the periplasmic 
membrane fusion protein CusB.  
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Results  
Overall structure of CusB 
We cloned, expressed and purified the full-length CusB protein containing a 6xHis tag 
at the C-terminus.  We obtained crystals of the E. coli CusB efflux protein in detergent 
following an extensive screening for crystallization conditions.  We then used the multiple-
wavelength anomalous dispersion method to solve the selenomethionyl-substituted (SeMet) 
CusB crystal structure.  The resulting experimental electron density maps shown in Figure 1 
revealed that the asymmetric unit of the CusB crystal consists of two protomers (labeled A and 
B).  These two molecules are related to each other by an approximately twofold symmetry.  
The native crystal structure of CusB was then determined to a resolution of 3.4 Å (Table 1), 
revealing that the A molecule of CusB is folded into an elongated polypeptide of ~121 Å long 
and ~37 Å wide; whereas the dimensions of the B molecule are ~116 Å long and ~40 Å wide.  
The mature protein of CusB consists of 379 amino acids (residues 29 through 407).  Currently, 
78.1% of the residues are included in our final model.   
Intriguingly, the crystal structure suggested that each elongated molecule of CusB can 
be divided into four different domains (Figure 2).  The first three domains of the protein are 
mostly β-strands.  However, the fourth domain forms an all α-helical domain, which is folded 
into a three-helix bundle secondary structure.  Alignment of amino acid sequences indicates 
that CusB shares 13% identity and 52% similarity to that of MexA.  The alignment also shows 
an overall identity and homology of 16% and 54% to AcrA, respectively.  Because of the 
relatively low sequence identity, it is not surprising that the crystal structure of CusB is quite 
different from the known structures of MexA25-27 and AcrA.24 
The β-strand domains 
As mentioned earlier, each CusB molecule consists of three different β-domains.  The 
first β-domain (Domain 1) is formed by the N and C-terminal ends of the polypeptide (residues 
89-102 and 324-385).  Presumably, this domain is located directly above the outer-leaflet of the 
inner membrane and interacts with the CusA efflux pump.  Overall, Domain 1 in molecule A is 
a β-barrel domain.  It is composed of six β-strands, with the N-terminal end forming one of the 
β-strands while the C-terminus of the protein constitutes the remaining five strands (Figure 2).  
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Domain 1 in molecule B of CusB exhibits an almost identical structure, which is also folded 
into a six β-barrel domain.   
The second β-domain (Domain 2) of CusB is formed by residues 105-115 and 243-320.  
In molecule A, this domain consists of six β-strands and one short α-helix.  Again, the N-
terminal residues form one of the β-strands that is incorporated into this domain.  The C-
terminal residues contribute a β-strand, an α-helix and four anti-parallel β-sheets.  In molecule 
B, this domain differs by assembling into six β-strands and two short α-helices.  In an 
asymmetric unit of the crystal, Domains 1 and 2 of molecule A interact closely with Domains 2 
and 1 of molecule B, respectively (Figure 1a).    
Domain 3 is another globular β-domain adjacent to the second domain of molecule A.  
This domain consists of residues 121-154 and 207-239, with a majority of these residues 
folding into eight β-strands.  Similar to that of molecule A, the corresponding domain in 
molecule B is also an eight β-barrel structure. 
The α-helical domain 
Perhaps the most interesting motif appears to be in the fourth domain (Domain 4) of 
CusB.  This region forms an all-helical domain.  In molecule A, this α-domain comprises 
residues 156-205.  Surprisingly, this domain is folded into an anti-parallel, three-helix bundle.  
This structural feature, not found in other known protein structures in the MFP family, 
highlights the uniqueness of the CusB protein.  The helix bundle creates an ~27 Å long helix-
turn-helix-turn-helix secondary structure, making it at least 20 Å shorter than the two-helical 
hairpin domains of MexA25-27 and AcrA.24  Domain 4 of molecule B exhibits a similar three-
helix bundle motif when compared to the secondary structure of molecule A.  To date, CusB is 
the only periplasmic protein in the MFP family that possesses this three-helical domain instead 
of a two-helical hairpin motif.  The overall structure of CusB is quite distinct from the known 
structures of other membrane fusion proteins. 
It is interesting to note that both crystals of CusB and MexA27 contain two copies of the 
molecules, each of which consists of four different domains.  We superimposed these protein 
structures and observed that the pair containing molecule A of CusB and the “unrotated” 
molecule of MexA displays the closest topological similarity (Figure 3).  A pairwise alignment 
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of these two structures is difficult because their detailed secondary structures are quite 
different.  We tried to superimpose the α-domains (Domain 4 of CusB and the α-hairpin 
domain of MexA) of these two structures together and found that these two α-domains cannot 
be aligned.  However, their individual β-domains can be superimposed separately.  For 
example, superposition of Domain 1 of CusB with the membrane proximal domain of MexA 
gives an overall rmsd of 2.4 Å calculated over the Cα atoms.  Domain 2 of CusB and the β-
barrel domain of MexA can also be superimposed, resulting in an overall rmsd of 2.0 Å.  
Likewise, Domain 3 of CusB can be paired up with the lipoyl domain of MexA, and this 
superimposition results in an overall rmsd of 1.8 Å. 
Conformational flexibility of CusB         
Two distinct conformations of CusB were captured in the single crystal, suggesting that 
the membrane fusion protein is quite flexible in nature.  A comparison of the A and B 
molecules of CusB indicates that these two molecules are quite different, presumably 
representing two transient states of the membrane fusion protein.  However, the two 
conformations are related, whereby a small hinge motion is attributed to the differences.  
Superimposition of these two molecules gives an overall rmsd of 2.6 Å calculated over the Cα 
atoms.  Comparison of these two structures reveals that molecule A adopts a more open 
conformation, while molecule B exhibits a relatively compact form of the structure (Figure 4).  
Thus, these two molecules may correspond to the open and closed states of the membrane 
fusion protein. 
It appears that Domains 1 + 2 of molecules A and B can easily be superimposed with 
high structural similarity, giving an overall rmsd of 0.8 Å (168 Cα atoms).  Superposition of 
Domains 3 + 4 alone of these two molecules can also be calculated, showing an overall rmsd of 
0.8 Å (118 Cα atoms).  Using Domain 1 + 2 as references, the α-helical domains of molecules 
A and B are found to differ by ~21o overall (Figure 4a).  When Domains 3 + 4 are 
superimposed, the orientation of the β-barrels of Domain 1 in molecules A and B display an 
overall shift of ~23o (Figure 4b).  Taken together, these superimpositions suggest that the linker 
region, which is composed of two loops (residues 116-120 and 240-242) between Domains 2 
and 3, forms a flexible hinge in the membrane fusion protein.  This hinge region effectively 
permits the protein to shift from one conformation to another simply by performing a rigid-
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body movement at Domains 1 + 2 with respect to Domains 3 + 4.  The two structures of CusB 
found in a single crystal indeed underscore the conformational flexibility of this membrane 
fusion protein. 
Discussion 
In this study, we presented the crystal structure of the membrane fusion protein CusB, 
an essential component in the CusABC efflux system which extrudes silver and copper ions 
from E. coli.  This is the first structure of any membrane fusion protein that is associated with 
an HME-RND-type transporter.  Currently, CusB and MexA27 exhibit the most complete three-
dimensional structures among those resolved for membrane fusion proteins, including AcrA24 
and MacA.28  The overall structures of MexA, AcrA and MacA are very similar to each other.  
For example, a superposition of 183 Cα atoms of AcrA with their corresponding residues in the 
MexA structure gives an overall rmsd of 0.8 Å.24  CusB, however, is folded into a very unique 
secondary structure when compared with the current crystal structures of other membrane 
fusion proteins.  Like MexA, the structure of CusB revealed that this membrane fusion protein 
consists of four major domains, including three β-strand domains and one α-helical domain.  
Strikingly, the α-helical domain of CusB features a three-helix bundle which contrasts other 
structures of membrane fusion proteins.  This structural feature, not found in other members of 
the MFP family, may underscore the unique functionality of CusB.  Thus, CusB may utilize a 
different mechanism to facilitate metal ion transport in the RND family.  The distinct 
secondary structure of CusB may also imply that its tripartite partners, the inner membrane 
transporter CusA and the outer membrane channel CusC, may also possess unique secondary 
structural features that distinguish them from the existing structures of their homologous 
proteins.  Exactly how these individual heavy-metal efflux components assemble into a 
functional complex must await the elucidation of the CusA and CusC structures.  
The crystal structure of CusB demonstrated that this protein exists in two distinct 
conformations, one of which presents a more open form while the other exhibits a more 
compact structure.  In the crystal lattice, these two molecules (molecules A and B) interact with 
one another to form a dimer.  It should be noted that this dimeric arrangement might not be 
biologically relevant because, similar to the other isolated membrane fusion proteins associated 
with the HAE-RND family, in vitro study indicated that CusB exists a monomer in solution.29  
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Thus, the functional form of CusB in solution is most likely to be monomeric.  The two distinct 
conformations of CusB, however, may represent two different transient states of the protein, 
i.e. the apo and metal-bound forms.  Analytical gel filtration experiments suggested that the 
conformation of CusB shifts to a more compact state upon binding Ag(I).29  Thus, it is likely 
that the compact structure, represented by molecule B of CusB, may mimic the metal-bound 
form of the protein. 
The fact that two copies of CusB have been found in a single crystal highlights the 
conformational flexibility of this membrane fusion protein.  The flexible nature of these 
membrane fusion proteins has also been observed with MexA, AcrA and MacA.  There is a 
good chance that conformational flexibility is a common feature among members of the MFP 
family.  Indeed, four different conformations of AcrA have been identified within a single 
crystal.24 
Based on experimental results from extended x-ray absorption fine structure (EXAFS) 
and site-specific mutagenesis,29 it has been proposed that residues M49, M64 and M66 of 
CusB form a three-coordinate metal-binding site for Cu+ and Ag+.  These residues are located 
at the N-terminal end of CusB, a region that is intrinsically disordered and cannot be identified 
in the electron density maps of our crystals.  Thus, these residues were excluded in our model.  
Potentially, these methionine residues could form an ideal binding site for Cu(I)/Ag(I).  
According to the crystal structures of CusB, this proposed Cu(I)/Ag(I) binding site may be 
located right above the inner membrane, adjacent to the periplasmic domain of the CusA efflux 
pump.  It is possible that this proposed metal binding site might directly interact with this 
membrane protein.  If this is the case, CusB may capture the metal that is released from CusA 
through this proposed metal binding site.  In addition, if the α-helices at Domain 4 of CusB 
interact with the outer membrane channel CusC, this implies that CusB may be involved in 
delivering the bound metal ions to CusC and eventually exporting the metal ions from the cell.  
It has also been proposed that CusB directly interacts with the chaperone CusF,30,31 which 
captures the metal ions in the periplasm.  There is a chance that the metal ions could be 
transferred from this chaperone protein to CusB for export.  Further experimental evidence is 
needed to understand the detailed mechanisms of metal ion extrusion in this system. 
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The mature protein of CusB consists of nine methionine residues.  Four of these 
methionines are located at one end of the disordered region formed by the N and C-termini of 
the protein.  Three of these four methionines, M49, M64 and M66, have been proposed to form 
a three-methionine metal binding site.29  Surprisingly, the remaining five methionine residues 
do not pair up with each other but distribute through the entire length of the protomer.  So far, 
all available structures of copper tolerance proteins, including CusF,30,31 CueR32 and Atx1,33 
indicate that these proteins carry their Ag(I) or Cu(I) cargo in either two-methionine or two-
cysteine binding pockets.  The bound monovalent metal ions are usually further anchored by 
histidine and/or tryptophan side chains to secure the binding.  Thus, it is uncertain if these five 
separate methionines could accommodate the binding of Ag(I) and Cu(I).  To elucidate if the 
CusB structure potentially forms ligand-binding sites, we used the program “putative active 
sites with spheres” (PASS)34 to search for these sites.  It turned out PASS suggests that the top 
predicted site is located in the vicinity of the hinge region between Domains 2 and 3.  
Surrounding this potential binding site are residues K143, M241 and K308 (Figure 5).  
Although, lysine has been reported to interact with Cu+ by capturing and releasing the bound 
metal ion in the yeast metallochaperone Atx1,33 this site only contains one methionine.  It is not 
certain if this predicted site could bind metal ions.     
There is evidence that members of the MFP family play a functional role in the efflux 
of substrates. It has been found that the MFP EmrA is able to directly bind different transported 
drugs.35  Recently, the CusB protein has also been shown to interact with Ag(I).29  Thus, in 
addition to their role as adaptors to bridge the inner and outer membrane efflux components, 
these membrane fusion proteins may participate in recognizing and extruding their substrates.  
Exactly how CusB binds heavy metals is not clear.  The crystal structures of CusB-Ag(I) and 
CusB-Cu(I) complexes would be necessary to understand how this membrane fusion protein 
interacts with metal ions.    
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Materials and Methods 
Cloning, expression and purification 
For cloning cusB, the ORF of cusB from E. coli K12 chromosomal DNA was amplified 
by PCR using the primers 5'-AAACCATGGGCAAAAAAATCGCGCTTATTATCGGC-3' 
and  5'-
AAAGGATCCTCAATGGTGATGGTGATGATGATGCGCATGGGTAGCACTTTCAG-3' 
to generate a product that would encode a CusB recombinant protein with a 6xHis tag at the C-
terminus.  The corresponding 1,224 bp PCR fragment was extracted from the agarose gel, 
digested with NcoI and BamHI (New England Biolabs), and cloned into the pET15b to form 
the expression vector, pET15bΩcusB.  The recombinant plasmids were transformed into DH5α 
cells and selected on LB plates containing 100 µg/ml ampicillin.  The construction was verified 
by DNA sequencing. 
The full-length CusB membrane fusion protein containing a 6xHis tag at the C-
terminus was overproduced in E. coli BL21(DE3) cells possessing pET15bΩcusB.  Briefly, 
cells were grown in 12 L of Luria Bertani (LB) medium containing 100 µg/ml ampicillin at 
37oC.  The culture was induced with 1 mM isopropyl β-D-thiogalactopyranoside (IPTG) at 
OD600 value of approximately 0.5.  Cells were harvested within 4 h of induction.  The collected 
bacteria were resuspended in ice-cold buffer containing 20 mM Na-HEPES (pH 7.2) and 100 
mM NaCl.  The cells were then lysed in a French pressure cell.  Cell debris was removed by 
centrifugation for 45 min at 4oC and 20,000 rev/min.  The crude lysate was collected and 0.5% 
n-dodecyl-β-D-maltoside (DDM) was added into the protein solution.  The protein solution 
was then purified with Ni2+-affinity and G-200 sizing columns.  The purity of the protein (> 
95%) was judged using 10% SDS-PAGE stained with Coomassie Brilliant Blue.  The N-
terminal sequence of the CusB protein was confirmed by sequencing.  The purified CusB 
protein was then concentrated to 20 mg/ml in a buffer containing 20 mM Na-HEPES (pH 7.5) 
and 0.04% DDM for crystallization. 
For 6xHis SeMet-CusB protein expression, a 10 ml LB broth overnight culture 
containing E. coli B834/ pET15bΩcusB cells was transferred into 120 ml of LB broth 
containing 100 µg/ml ampicillin and grown at 37oC.  When the OD600 value reached 1.2, cells 
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were harvested by centrifugation at 6000 rev/min for 10 min, and then washed two times with 
20 ml of M9 minimal salts solution.  The cells were re-suspended in 120 ml of M9 media and 
then transferred into a 12 L pre-warmed M9 solution containing 100 µg/ml ampicillin.  The 
cell culture was incubated at 37oC with shaking. When the OD600 reached 0.4, 60 mg/l of L-
selenomethionine were added. The culture was induced with 1 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) after 15 min.  Cells were then harvested within 4 h after 
induction.  The procedures for purifying the 6xHis SeMet-CusB were identical to those of the 
native protein. 
Crystallization, data collection, structural determination and refinement 
Crystals of the 6xHis CusB were obtained using hanging-drop vapor diffusion.  The 
CusB crystals were grown at room temperature in 24-well plates with the following 
procedures.  A 2 µl protein solution containing 20 mg/ml CusB protein in 20 mM Na-HEPES 
(pH 7.5) and 0.04% (w/v) DDM was mixed with a 2 µl of reservoir solution containing 15% 
PEG 1000, 0.1 M Na-citrate (pH 5.6), 0.36 M Na-citrate, 5% isopropanol and 5% glycerol.  
The resultant mixture was equilibrated against 500 µl of the reservoir solution.  The 
crystallization conditions for SeMet-CusB were the same as those for the native CusB protein.  
Crystals of CusB grew to a full size in the drops within a month.  Typically, the dimensions of 
the crystals were 0.4 mm x 0.4 mm x 0.1 mm.  Cryoprotection was achieved by raising the 
PEG 1000 concentration stepwise to 30% with a 5% increment in each step. 
All diffraction data sets were collected at 100 K in the Advanced Photon Source 
(beamline 24-ID-C) using an ADSC Quantum 315 CCD-based detector.  Diffraction data were 
processed with DENZO and scaled with SCALEPACK.36  Both the native and SeMet crystals 
took the space group of I222, with unit cell parameters very similar to each other (Table 1).  
The structure of CusB was determined by the multiple-wavelength anomalous dispersion 
(MAD) method.  Phase refinement was carried out using the program AutoSHARP.37  The 
electron density map was then subjected to density modification using the program 
RESOLVE.38  After tracing the initial model manually in the program Coot,39 the model was 
then refined against the native data at 3.4 Å resolution using CNS40 and PHENIX.41 
 
Accession Numbers 
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Coordinates and structural factors have been deposited in the Protein Data Bank with 
accession number 3H9I. 
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Legends of Figures 
Figure 1a 
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Figure 1b 
 
Figure 1.  Stereo view of the experimental electron density map at a resolution of 3.8 Å.  (a) 
The electron density map contoured at 1.2 
CusB are in orange and green, respectively.  (b) Representative se
in the second domain of CusB.  The electron density (colored blue) is contoured at the 1.2 
level and superimposed with the final refined model (orange, carbon; red, oxygen; blue, 
nitrogen). 
 
112 
 
 
σ is in gray.  The Cα traces of molecules A and B of 
ction of the electron density 
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 Figure 2.  Crystal structure of the CusB membrane fusion protein.  The structure can be divided 
into four distinct domains.  Domain 1 is formed by the N and C
the inner membrane.  The loops between Domains 2 and 3 appear to form an effective hinge to 
allow the molecule to shift from an open conformation to a more compact structure.  Domain 4 
is folded into an anti-parallel, three
membrane. 
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Figure 3.  Structural comparison of the membrane fusion proteins.  (a) Superimposition of the 
crystal structures of CusB (orange) and MexA (purple).  (b) Superimposition of Domain 1 of 
CusB (orange) with the membrane proximal domain of MexA (purple).  (c) Superimposition of 
Domain 2 of CusB (orange) with the β-barrel domain of MexA (purple).  (d) Superimposition 
of Domain 3 of CusB (orange) with the lipoyl domain of MexA (purple). 
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Figure 4.  Comparison of the two conformations of CusB observed in the crystal.  (a) 
Superposition of Domains 1 + 2 of molecule A onto Domains 1 + 2 of molecule B, displaying 
an ~21o overall shift of the three-helix bundle of Domain 4.  (b) Superposition of Domains 3 + 
4 of molecule A onto Domains 3 + 4 of molecule B, displaying an overall shift of the β-strands 
of Domain 1 by ~23o. 
  
 Figure 5.  Binding site prediction for CusB.  This predicted binding site is located at the hinge 
region between Domains 2 and 3 of CusB.  Residues K143, M241 and K308 are shown as stick 
models (yellow, carbon; blue, nitrogen; orange, sulfur).
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Table 1.  Data collection, phasing and structural refinement statistics. 
  Native 
SeMet 
remote 
SeMet  
peak 
SeMet 
inflect. pt. 
Data Collection         
Detector type/source 
ADSQ 
Q315/ 
ADSQ 
Q315/ 
ADSQ 
Q315/ 
ADSQ 
Q315/ 
 APS-24IDC APS-24IDC APS-24IDC APS-24IDC 
Wavelength (Å) 1.008 0.9636 0.9792 0.9793 
Space group I222 I222 I222 I222 
Resolution (Å) 3.40 3.85 3.83 3.98 
Total reflections 49,228 68,943 142,012 77,254 
Unique reflections 17,168 12,449 12,596 11,322 
Completeness (%) 94.6 (92.2) 95.8 (85.0) 99.6 (99.3) 96.4 (88.7) 
Rsym (%) 4.6 (38.8) 8.4 (49.1) 8.9 (42.8) 9.4 (45.2) 
Average I/σ(I) 19.7 (1.7) 16.5 (2.2) 27.5 (4.5) 21.3 (2.9) 
Phasing         
Phasing power   1.93  
Rcullis   0.89  
Figure of merit   0.40/0.26  
(acentric/centric)     
Figure of merit   0.66/0.62  
after density modification     
     
Refinement CusB       
Resolution (Å) 50-3.40       
Rwork (%) 26.5    
Rfree (%) 31.7    
Protein residues built 592    
rms deviation from ideal     
      Bond lengths (Å) 0.008    
      Bond angles (°) 1.6       
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CHAPTER 8.General Conclusion and Future Direction 
The transport cycle of multidrug efflux pumps must involve various conformational 
states, including substrate binding and translocation.  We have detected the binding affinity of 
different substrates to the AcrB RND-type transporter.  We have also determined structures 
of different conformational states of AcrB using x-ray crystallography.  The key question in 
these efflux systems is the pathway for substrate translocation and it remains unknown.  
Combining with site-specific mutagenesis and single molecule technique, we should be able 
to develop a three-color FRET system and observe the phenomenon of substrate 
translocation.  In the future, we will perform research work in this direction.  Using single 
molecule technique, we should be able to observe a sequential change in FRET signal during 
drug export.  Thus, this approach should allow us to differentiate different stages of the 
transport cycle.     
The crystal structures of different membrane fusion proteins, including CusB, MexA 
and AcrA, indicate that these proteins are flexible in nature.  The role of these flexible 
proteins and how they interact with their substrates is still not clear.  Recent advances in 
NMR spectroscopy have led us to measure heteronuclear multi-dimensional NMR signal of 
macromolecules inside living cells.  This method, so-called in-cell NMR, has allowed in vivo 
observations of the structures and dynamics of biomoleules.  It is thought that this method is 
suitable for use in studying protein-ligand interaction inside the living cell.  We can use in-cell 
NMR spectroscopy to understand the functional role of membrane fusion proteins.  By 
controlling the energy source and concentration of transported ligands, we should be able to 
observe different conformations of these membrane fusion proteins at various functional states.  
It is certain that multidrug efflux transporters interfere significantly with the treatment 
of bacterial infections, by recognizing a number of structurally unrelated toxic compounds and 
actively extruding them from cells.  Thus, these efflux transporters are clinically relevant and 
understanding the structural aspect of these proteins potentially can offer us for new drug 
targets.  A more fundamental role for bacterial efflux transporters may be their contribution to 
the survival of bacteria during exposure to antimicrobial agents and toxic compounds.  This 
may contribute to the survival of certain species within their ecological niche.  While no efflux 
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transporter inhibitor has yet reach clinical practice, it is clear that this area of drug development 
offers a promising avenue and is considered to be of great clinical value. 
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